Madsen and Bugge, http://www.jcb.org/cgi/content/full/jcb.201501034/DC1

Studies of protease localization in human breast cancer

Al-Raawi, D., H. Abu-El-Zahab, M. El-Shinawi, and M.M. Mohamed. 2011. Membrane type-1 matrix metalloproteinase (MT1-MMP) correlates with the expression and activation of matrix metalloproteinase-2 (MMP-2) in inflammatory breast cancer. *Int. J. Clin. Exp. Med*. 4:265–275.

Atik, E., B. Akansu, S. Bakaris, and N. Aban. 2010. Expression of cyclooxygenase-2 and its relation to histological grade, inducible nitric oxide synthase, matrix metalloproteinase-2, CD-34, Caspase-3, and CD8 in invasive ductal carcinoma of the breast. *Saudi Med. J.* 31:130–134.

Bachmeier, B.E., H. Rohrbach, J. De Waal, M. Jochum, and A.G. Nerlich. 2005. Enhanced expression and activation of major matrix metalloproteinases in distinct topographic areas of invasive breast carcinomas. *Int. J. Oncol.* 26:1203–1207.

Bagnoli, F., V.M. Oliveira, M.A. Silva, G.C. Taromaru, J.F. Rinaldi, and T. Aoki. 2010. The interaction between aromatase, metalloproteinase 2,9 and CD44 in breast cancer. *Rev. Assoc. Med. Bras.* 56:472–477. http://dx.doi.org/10.1590/S0104-42302010000400023

Baker, E.A., T.J. Stephenson, M.W. Reed, and N.J. Brown. 2002. Expression of proteinases and inhibitors in human breast cancer progression and survival. *Mol. Pathol.* 55:300–304. http://dx.doi.org/10.1136/mp.55.5.300

Behrens, P., M. Rothe, A. Wellmann, J. Krischler, and N. Wernert. 2001. The Ets-1 transcription factor is up-regulated together with MMP 1 and MMP 9 in the stroma of pre-invasive breast cancer. *J. Pathol.* 194:43–50. http://dx.doi.org/10.1002/path.844

Bisson, C., S. Blacher, M. Polette, J.F. Blanc, F. Kebers, J. Desreux, B. Tetu, J. Rosenbaum, J.M. Foidart, P. Birembaut, and A. Noel. 2003. Restricted expression of membrane type 1-matrix metalloproteinase by myofibroblasts adjacent to human breast cancer cells. *Int. J. Cancer*. 105:7–13. http://dx.doi.org/10.1002/ijc.11012

Boström, P., M. Söderström, T. Vahlberg, K.O. Söderström, P.J. Roberts, O. Carpén, and P. Hirsimäki. 2011. MMP-1 expression has an independent prognostic value in breast cancer. *BMC Cancer*. 11:348. http://dx.doi.org/10.1186/1471-2407-11-348

Brummer, O., S. Athar, L. Riethdorf, T. Löning, and H. Herbst. 1999. Matrix-metalloproteinases 1, 2, and 3 and their tissue inhibitors 1 and 2 in benign and malignant breast lesions: an in situ hybridization study. *Virchows Arch.* 435:566–573. http://dx.doi.org/10.1007/s004280050442

Carriero, M.V., P. Franco, S. Del Vecchio, O. Massa, G. Botti, G. D'Aiuto, M.P. Stoppelli, and M. Salvatore. 1994. Tissue distribution of soluble and receptor-bound urokinase in human breast cancer using a panel of monoclonal antibodies. *Cancer Res.* 54:5445–5454.

Castelló, R., J.M. Landete, F. España, C. Vázquez, C. Fuster, S.M. Almenar, L.A. Ramón, K.P. Radtke, and A. Estellés. 2007. Expression of plasminogen activator inhibitors type 1 and type 3 and urokinase plasminogen activator protein and mRNA in breast cancer. *Thromb. Res.* 120:753–762. http://dx.doi.org/10.1016/j.thromres.2006.12.016

Caudroy, S., M. Polette, J.M. Tournier, H. Burlet, B. Toole, S. Zucker, and P. Birembaut. 1999. Expression of the extracellular matrix metalloproteinase inducer (EMMPRIN) and the matrix metalloproteinase-2 in bronchopulmonary and breast lesions. *J. Histochem. Cytochem.* 47:1575–1580. http://dx.doi.org/10.1177/002215549904701209

Chang, H.J., M.J. Yang, Y.H. Yang, M.F. Hou, E.J. Hsueh, and S.R. Lin. 2009. MMP13 is potentially a new tumor marker for breast cancer diagnosis. *Oncol. Rep.* 22:1119–1127.

Chazaud, B., R. Ricoux, C. Christov, A. Plonquet, R.K. Gherardi, and G. Barlovatz-Meimon. 2002. Promigratory effect of plasminogen activator inhibitor-1 on invasive breast cancer cell populations. *Am. J. Pathol.* 160:237–246. http://dx.doi.org/10.1016/S0002-9440(10)64367-2

Chenard, M.P., Y. Lutz, A. Mechine-Neuville, I. Stoll, J.P. Bellocq, M.C. Rio, and P. Basset. 1999. Presence of high levels of MT1-MMP protein in fibroblastic cells of human invasive carcinomas. *Int. J. Cancer*. 82:208–212. http://dx.doi.org/10.1002/(SICI)1097-0215(19990719)82:2<208::AID-IJC10>3.0.CO;2-9

Christensen, L., A.C. Wiborg Simonsen, C.W. Heegaard, S.K. Moestrup, J.A. Andersen, and P.A. Andreasen. 1996. Immunohistochemical localization of urokinase-type plasminogen activator, type-1 plasminogen-activator inhibitor, urokinase receptor and alpha(2)-macroglobulin receptor in human breast carcinomas. *Int. J. Cancer*. 66:441–452. http://dx.doi.org/10.1002/(SICI)1097-0215(19960516)66:4<441::AID-IJC6>3.0.CO;2-W

Cierna, Z., M. Mego, P. Janega, M. Karaba, G. Minarik, J. Benca, T. Sedlácková, S. Cingelova, P. Gronesova, D. Manasova, et al. 2014. Matrix metalloproteinase 1 and circulating tumor cells in early breast cancer. *BMC Cancer*. 14:472. http://dx.doi.org/10.1186/1471-2407-14-472

Clavel, C., G. Chavanel, and P. Birembaut. 1986. Detection of the plasmin system in human mammary pathology using immunofluorescence. *Cancer Res.* 46:5743–5747.

Clavel, C., M. Polette, M. Doco, I. Binninger, and P. Birembaut. 1992. Immunolocalization of matrix metallo-proteinases and their tissue inhibitor in human mammary pathology. *Bull. Cancer*. 79:261–270.

Costantini, V., A. Sidoni, R. Deveglia, O.A. Cazzato, G. Bellezza, I. Ferri, E. Bucciarelli, and G.G. Nenci. 1996. Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: an immunohistochemical comparison of normal, benign, and malignant breast tissues. *Cancer*. 77:1079–1088. http://dx.doi.org/10.1002/(SICI)1097-0142(19960315)77:6<1079::AID-CNCR12>3.0.CO;2-Z

Costantini, V., L.R. Zacharski, V.A. Memoli, B.J. Kudryk, S.M. Rousseau, and D.C. Stump. 1991. Occurrence of components of fibrinolysis pathways in situ in neoplastic and nonneoplastic human breast tissue. *Cancer Res.* 51:354–358.

D'Andrea, M.R., M.R. Limiti, M. Bari, P. Zambenedetti, A. Montagutti, F. Ricci, G.L. Pappagallo, D. Sartori, O. Vinante, and P.L. Mingazzini. 2007. Correlation between genetic and biological aspects in primary non-metastatic breast cancers and corresponding synchronous axillary lymph node metastasis. *Breast Cancer Res. Treat.* 101:279–284. http://dx.doi.org/10.1007/s10549-006-9300-2

Dacic, S., S. Kounelis, E. Kouri, and M.W. Jones. 2002. Immunohistochemical profile of cystosarcoma phyllodes of the breast: a study of 23 cases. *Breast J.* 8:376–381. http://dx.doi.org/10.1046/j.1524-4741.2002.08608.x

Dalberg, K., E. Eriksson, U. Enberg, M. Kjellman, and M. Bäckdahl. 2000. Gelatinase A, membrane type 1 matrix metalloproteinase, and extracellular matrix metalloproteinase inducer mRNA expression: correlation with invasive growth of breast cancer. *World J. Surg.* 24:334–340. http://dx.doi.org/10.1007/S002689910053

Damjanovich, L., C. Turzó, and R. Adány. 1994. Factors involved in the plasminogen activation system in human breast tumours. *Thromb. Haemost.* 71:684–691.

Davidson, B., S. Konstantinovsky, S. Nielsen, H.P. Dong, A. Berner, M. Vyberg, and R. Reich. 2004. Altered expression of metastasis-associated and regulatory molecules in effusions from breast cancer patients: a novel model for tumor progression. *Clin. Cancer Res.* 10:7335–7346. http://dx.doi.org/10.1158/1078-0432.CCR-04-0183

Davies, B., D.W. Miles, L.C. Happerfield, M.S. Naylor, L.G. Bobrow, R.D. Rubens, and F.R. Balkwill. 1993. Activity of type IV collagenases in benign and malignant breast disease. *Br. J. Cancer*. 67:1126–1131. http://dx.doi.org/10.1038/bjc.1993.207

del Casar, J.M., G. Carreño, L.O. González, S. Junquera, S. González-Reyes, J.M. González, M. Bongera, A.M. Merino, and F.J. Vizoso. 2010a. Expression of metalloproteases and their inhibitors in primary tumors and in local recurrences after mastectomy for breast cancer. *J. Cancer Res. Clin. Oncol.* 136:1049–1058. http://dx.doi.org/10.1007/s00432-009-0750-x

Del Casar, J.M., L.O. González, E. Alvarez, S. Junquera, L. Marín, L. González, M. Bongera, J. Vázquez, and F.J. Vizoso. 2009. Comparative analysis and clinical value of the expression of metalloproteases and their inhibitors by intratumor stromal fibroblasts and those at the invasive front of breast carcinomas. *Breast Cancer Res. Treat.* 116:39–52. http://dx.doi.org/10.1007/s10549-009-0351-z

Del Casar, J.M., S. González-Reyes, L.O. González, J.M. González, S. Junquera, M. Bongera, M.F. García, A. Andicoechea, C. Serra, and F.J. Vizoso. 2010b. Expression of metalloproteases and their inhibitors in different histological types of breast cancer. *J. Cancer Res. Clin. Oncol.* 136:811–819. http://dx.doi.org/10.1007/s00432-009-0721-2

Djonov, V., N. Cresto, D.M. Aebersold, P.H. Burri, H.J. Altermatt, M. Hristic, G. Berclaz, A. Ziemiecki, and A.C. Andres. 2002. Tumor cell specific expression of MMP-2 correlates with tumor vascularisation in breast cancer. *Int. J. Oncol.* 21:25–30.

Dublin, E., A. Hanby, N.K. Patel, R. Liebman, and D. Barnes. 2000. Immunohistochemical expression of uPA, uPAR, and PAI-1 in breast carcinoma. Fibroblastic expression has strong associations with tumor pathology. *Am. J. Pathol.* 157:1219–1227. http://dx.doi.org/10.1016/S0002-9440(10)64637-8

Eiró, N., I. Pidal, B. Fernandez-Garcia, S. Junquera, M.L. Lamelas, J.M. del Casar, L.O. González, A. López-Muñiz, and F.J. Vizoso. 2012. Impact of CD68/(CD3+CD20) ratio at the invasive front of primary tumors on distant metastasis development in breast cancer. *PLoS ONE*. 7:e52796. http://dx.doi.org/10.1371/journal.pone.0052796

Escot, C., Y. Zhao, C. Puech, and H. Rochefort. 1996. Cellular localisation by in situ hybridisation of cathepsin D, stromelysin 3, and urokinase plasminogen activator RNAs in breast cancer. *Breast Cancer Res. Treat.* 38:217–226. http://dx.doi.org/10.1007/BF01806676

Fernández-Guinea, O., A. Álvarez-Cofiño, N. Eiró, L.O. González, J.M. del Casar, B. Fernandez-Garcia, M.L. Lamelas, A. Andicoechea, and F.J. Vizoso. 2013. Low microvascular density at the tumor center is related to the expression of metalloproteases and their inhibitors and with the occurrence of distant metastasis in breast carcinomas. *Int. J. Clin. Oncol.* 18:629–640. http://dx.doi.org/10.1007/s10147-012-0428-2

Ferrier, C.M., H.H. de Witte, H. Straatman, D.H. van Tienoven, W.L. van Geloof, F.J. Rietveld, C.G. Sweep, D.J. Ruiter, and G.N. van Muijen. 1999. Comparison of immunohistochemistry with immunoassay (ELISA) for the detection of components of the plasminogen activation system in human tumour tissue. *Br. J. Cancer*. 79:1534–1541. http://dx.doi.org/10.1038/sj.bjc.6690245

Fisher, J.L., C.L. Field, H. Zhou, T.L. Harris, M.A. Henderson, and P.F. Choong. 2000. Urokinase plasminogen activator system gene expression is increased in human breast carcinoma and its bone metastases—a comparison of normal breast tissue, non-invasive and invasive carcinoma and osseous metastases. *Breast Cancer Res. Treat.* 61:1–12. http://dx.doi.org/10.1023/A:1006445129195

Folgueira, M.A., S. Maistro, M.L. Katayama, R.A. Roela, F.G. Mundim, S. Nanogaki, G.H. de Bock, and M.M. Brentani. 2013. Markers of breast cancer stromal fibroblasts in the primary tumour site associated with lymph node metastasis: a systematic review including our case series. *Biosci. Rep.* 33:e00085. http://dx.doi.org/10.1042/BSR20130060

Fujiwara, A., E. Shibata, H. Terashima, A. Shishido, J. Nishiki, K. Yoshida, K. Miyauchi, A. Madachi, and N. Matsuura. 2006. Evaluation of matrix metalloproteinase-2 (MMP-2) activity with film in situ zymography for improved cytological diagnosis of breast tumors. *Breast Cancer*. 13:272–278. http://dx.doi.org/10.2325/jbcs.13.272

García, M.F., S. González-Reyes, L.O. González, S. Junquera, N. Berdize, J.M. Del Casar, M. Medina, and F.J. Vizoso. 2010. Comparative study of the expression of metalloproteases and their inhibitors in different localizations within primary tumours and in metastatic lymph nodes of breast cancer. *Int. J. Exp. Pathol.* 91:324–334. http://dx.doi.org/10.1111/j.1365-2613.2010.00709.x

Giannelli, G., E. Fransvea, F. Marinosci, C. Bergamini, A. Daniele, S. Colucci, A. Paradiso, M. Quaranta, and S. Antonaci. 2002. Gelatinase levels in male and female breast cancer. *Biochem. Biophys. Res. Commun.* 292:161–166. http://dx.doi.org/10.1006/bbrc.2002.6599

Göhring, U.J., A. Scharl, U. Thelen, A. Ahr, and G. Crombach. 1996. Comparative prognostic value of Cathepsin D and urokinase plasminogen activator, detected by immunohistochemistry, in primary breast carcinoma. *Anticancer Res.* 16:1011–1018.

Gonzalez, L.O., M.D. Corte, J. Vazquez, S. Junquera, R. Sanchez, A.C. Alvarez, J.C. Rodriguez, M.L. Lamelas, and F.J. Vizoso. 2008a. Androgen receptor expresion in breast cancer: relationship with clinicopathological characteristics of the tumors, prognosis, and expression of metalloproteases and their inhibitors. *BMC Cancer*. 8:149. http://dx.doi.org/10.1186/1471-2407-8-149

Gonzalez, L.O., M.D. Corte, J. Vazquez, S. Junquera, R. Sanchez, A. Viña, J.C. Rodriguez, M.L. Lamelas, and F. Vizoso. 2008b. Study of matrix metalloproteinases and their tissue inhibitors in ductal in situ carcinomas of the breast. *Histopathology*. 53:403–415. http://dx.doi.org/10.1111/j.1365-2559.2008.03136.x

González, L.O., S. González-Reyes, S. Junquera, L. Marín, L. González, J.M. Del Casar, J.M. González, and F. Vizoso. 2010. Expression of metalloproteases and their inhibitors by tumor and stromal cells in ductal carcinoma in situ of the breast and their relationship with microinvasive events. *J. Cancer Res. Clin. Oncol.* 136:1313–1321. http://dx.doi.org/10.1007/s00432-010-0782-2

González, L.O., I. Pidal, S. Junquera, M.D. Corte, J. Vázquez, J.C. Rodríguez, M.L. Lamelas, A.M. Merino, J.L. García-Muñiz, and F.J. Vizoso. 2007. Overexpression of matrix metalloproteinases and their inhibitors in mononuclear inflammatory cells in breast cancer correlates with metastasis-relapse. *Br. J. Cancer*. 97:957–963.

Haas, S., T.W. Park, J.C. Hahne, and H.P. Fischer. 2008. Influence of preoperative core biopsies on uPA/PAI-1 expression in breast cancer tissue. *Virchows Arch.* 452:277–283. http://dx.doi.org/10.1007/s00428-007-0563-8

Harvey, S., S. Kohga, S.N. Sait, G. Markus, T.C. Hurd, M. Martinick, J. Geradts, R. Saxena, and J.F. Gibbs. 2009. Co-expression of urokinase with haptoglobin in human carcinomas. *J. Surg. Res.* 152:189–197. http://dx.doi.org/10.1016/j.jss.2008.06.016

Haupt, L.M., R.E. Irving, S.R. Weinstein, M.G. Irving, and L.R. Griffiths. 2008. Matrix metalloproteinase localisation by in situ-RT-PCR in archival human breast biopsy material. *Mol. Cell. Probes*. 22:83–89. http://dx.doi.org/10.1016/j.mcp.2007.06.009

Heppner, K.J., L.M. Matrisian, R.A. Jensen, and W.H. Rodgers. 1996. Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response. *Am. J. Pathol.* 149:273–282.

Hildenbrand, R., and A. Schaaf. 2009. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion. *Int. J. Oncol.* 34:15–23.

Hildenbrand, R., A. Schaaf, A. Dorn-Beineke, H. Allgayer, M. Sütterlin, A. Marx, and P. Stroebel. 2009. Tumor stroma is the predominant uPA-, uPAR-, PAI-1-expressing tissue in human breast cancer: prognostic impact. *Histol. Histopathol.* 24:869–877.

Hirvonen, R., A. Talvensaari-Mattila, P. Pääkkö, and T. Turpeenniemi-Hujanen. 2003. Matrix metalloproteinase-2 (MMP-2) in T(1-2)N0 breast carcinoma. *Breast Cancer Res. Treat.* 77:85–91. http://dx.doi.org/10.1023/A:1021152910976

Höyhtyä, M., R. Fridman, D. Komarek, K. Porter-Jordan, W.G. Stetler-Stevenson, L.A. Liotta, and C.M. Liang. 1994. Immunohistochemical localization of matrix metalloproteinase 2 and its specific inhibitor TIMP-2 in neoplastic tissues with monoclonal antibodies. *Int. J. Cancer*. 56:500–505. http://dx.doi.org/10.1002/ijc.2910560408

Hubbard, A.L., J. Lauder, R.A. Hawkins, and T.J. Anderson. 1995. Disregulation of urokinase plasminogen activator gene in breast cancer. *Eur. J. Cancer*. 31:103–107. http://dx.doi.org/10.1016/0959-8049(94)00430-D

Hurd, T.C., S. Sait, S. Kohga, J. Winston, M. Martinick, R. Saxena, H. Lankes, G. Markus, S. Harvey, and J.F. Gibbs. 2007. Plasminogen activator system localization in 60 cases of ductal carcinoma in situ. *Ann. Surg. Oncol.* 14:3117–3124. http://dx.doi.org/10.1245/s10434-007-9529-y

Ioannidis, I., B. Dimo, A. Karameris, G. Vilaras, H. Gakiopoulou, E. Patsouris, and A.C. Lazaris. 2010. Comparative study of the immunohistochemical expression of metalloproteinases 2, 7and 9between clearly invasive carcinomas and "in situ" trophoblast invasion. *Neoplasma*. 57:20–28. http://dx.doi.org/10.4149/neo_2010_01_020

Ishigaki, S., M. Toi, T. Ueno, H. Matsumoto, M. Muta, M. Koike, and M. Seiki. 1999. Significance of membrane type 1 matrix metalloproteinase expression in breast cancer. *Jpn. J. Cancer Res.* 90:516–522. http://dx.doi.org/10.1111/j.1349-7006.1999.tb00778.x

Ito, Y., T. Kobayashi, T. Takeda, E. Wakasugi, Y. Tamaki, Y. Nakano, N. Matsuura, and M. Monden. 1996. Immunolocalization of the components of the plasminogen activating system in breast carcinoma tissue. *Oncol. Rep.* 3:1021–1027.

Iwata, H., S. Kobayashi, H. Iwase, A. Masaoka, N. Fujimoto, and Y. Okada. 1996. Production of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human breast carcinomas. *Jpn. J. Cancer Res.* 87:602–611. http://dx.doi.org/10.1111/j.1349-7006.1996.tb00266.x

Izbicka, E., R.T. Streeper, I.T. Yeh, O. Pressley, M. Grant, J.V. Andrews, J. Kuhn, and J. O'Shaughnessy. 2010. Effects of alpha-difluoromethylornithine on markers of proliferation, invasion, and apoptosis in breast cancer. *Anticancer Res.* 30:2263–2269.

Jahkola, T., T. Toivonen, K. von Smitten, I. Virtanen, V.M. Wasenius, and C. Blomqvist. 1999. Cathepsin-D, urokinase plasminogen activator and type-1 plasminogen activator inhibitor in early breast cancer: an immunohistochemical study of prognostic value and relations to tenascin-C and other factors. *Br. J. Cancer*. 80:167–174. http://dx.doi.org/10.1038/sj.bjc.6690336

Jänicke, F., M. Schmitt, and H. Graeff. 1991. Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer. *Semin. Thromb. Hemost.* 17:303–312. http://dx.doi.org/10.1055/s-2007-1002624

Jankun, J., H.W. Merrick, and P.J. Goldblatt. 1993. Expression and localization of elements of the plasminogen activation system in benign breast disease and breast cancers. *J. Cell. Biochem.* 53:135–144. http://dx.doi.org/10.1002/jcb.240530206

Jones, J.L., P. Glynn, and R.A. Walker. 1999. Expression of MMP-2 and MMP-9, their inhibitors, and the activator MT1-MMP in primary breast carcinomas. *J. Pathol.* 189:161–168. http://dx.doi.org/10.1002/(SICI)1096-9896(199910)189:2<161::AID-PATH406>3.0.CO;2-2

Kennedy, S., M.J. Duffy, C. Duggan, C. Barnes, R. Rafferty, and M.D. Kramer. 1998. Semi-quantitation of urokinase plasminogen activator and its receptor in breast carcinomas by immunocytochemistry. *Br. J. Cancer*. 77:1638–1641. http://dx.doi.org/10.1038/bjc.1998.268

Kim, G.E., J.H. Kim, K.H. Lee, Y.D. Choi, J.S. Lee, J.H. Lee, J.H. Nam, C. Choi, M.H. Park, and J.H. Yoon. 2012. Stromal matrix metalloproteinase-14 expression correlates with the grade and biological behavior of mammary phyllodes tumors. *Appl. Immunohistochem. Mol. Morphol.* 20:298–303. http://dx.doi.org/10.1097/PAI.0b013e318235a132

Kim, H.J., C.I. Park, B.W. Park, H.D. Lee, and W.H. Jung. 2006. Expression of MT-1 MMP, MMP2, MMP9 and TIMP2 mRNAs in ductal carcinoma in situ and invasive ductal carcinoma of the breast. *Yonsei Med. J.* 47:333–342. http://dx.doi.org/10.3349/ymj.2006.47.3.333

Köhrmann, A., U. Kammerer, M. Kapp, J. Dietl, and J. Anacker. 2009. Expression of matrix metalloproteinases (MMPs) in primary human breast cancer and breast cancer cell lines: New findings and review of the literature. *BMC Cancer*. 9:188. http://dx.doi.org/10.1186/1471-2407-9-188

Lang, D.S., U. Heilenkötter, W. Schumm, O. Behrens, R. Simon, E. Vollmer, and T. Goldmann. 2013. Optimized immunohistochemistry in combination with image analysis: a reliable alternative to quantitative ELISA determination of uPA and PAI-1 for routine risk group discrimination in breast cancer. *Breast*. 22:736–743. http://dx.doi.org/10.1016/j.breast.2012.12.011

Lebeau, A., C. Müller-Aufdemkamp, C. Allmacher, U. Sauer, A. Nerlich, R. Lichtinghagen, and U. Löhrs. 2004. Cellular protein and mRNA expression patterns of matrix metalloproteinases-2, -3 and -9 in human breast cancer: correlation with tumour growth. *J. Mol. Histol.* 35:443–455. http://dx.doi.org/10.1023/B:HIJO.0000045943.26251.24

Lebeau, A., A.G. Nerlich, U. Sauer, R. Lichtinghagen, and U. Löhrs. 1999. Tissue distribution of major matrix metalloproteinases and their transcripts in human breast carcinomas. *Anticancer Res.* 19(5B):4257–4264.

Lhoták, S., L.J. Elavathil, S. Vukmirović-Popović, W.C. Duivenvoorden, R.G. Tozer, and G. Singh. 2000. Immunolocalization of matrix metalloproteinases and their inhibitors in clinical specimens of bone metastasis from breast carcinoma. *Clin. Exp. Metastasis*. 18:463–470. http://dx.doi.org/10.1023/A:1011800919981

Li, H.C., D.C. Cao, Y. Liu, Y.F. Hou, J. Wu, J.S. Lu, G.H. Di, G. Liu, F.M. Li, Z.L. Ou, et al. 2004. Prognostic value of matrix metalloproteinases (MMP-2 and MMP-9) in patients with lymph node-negative breast carcinoma. *Breast Cancer Res. Treat.* 88:75–85. http://dx.doi.org/10.1007/s10549-004-1200-8

Li, X., X. Kong, Y. Wang, and Q. Yang. 2013. 53BP1 is a novel regulator of angiogenesis in breast cancer. *Cancer Sci.* 104:1420–1426. http://dx.doi.org/10.1111/cas.12247

Liapis, G., E. Mylona, P. Alexandrou, I. Giannopoulou, I. Nikolaou, S. Markaki, A. Keramopoulos, and L. Nakopoulou. 2007. Effect of the different phosphorylated Smad2 protein localizations on the invasive breast carcinoma phenotype. *APMIS*. 115:104–114. http://dx.doi.org/10.1111/j.1600-0463.2007.apm_517.x

Lindsay, C.K., U.P. Thorgeirsson, H. Tsuda, and S. Hirohashi. 1997. Expression of tissue inhibitor of metalloproteinase-1 and type IV collagenase/gelatinase messenger RNAs in human breast cancer. *Hum. Pathol.* 28:359–366. http://dx.doi.org/10.1016/S0046-8177(97)90136-2

Lu, J., H. Li, D. Cao, G. Di, J. Wu, K. Sheng, Q. Han, Z. Shen, and Z. Shao. 2007. Clinical significance of aromatase protein expression in axillary node negative breast cancer. *J. Cancer Res. Clin. Oncol.* 133:401–409. http://dx.doi.org/10.1007/s00432-006-0186-5

Magkou, C., L. Nakopoulou, C. Zoubouli, K. Karali, I. Theohari, P. Bakarakos, and I. Giannopoulou. 2008. Expression of the epidermal growth factor receptor (EGFR) and the phosphorylated EGFR in invasive breast carcinomas. *Breast Cancer Res.* 10:R49. http://dx.doi.org/10.1186/bcr2103

Meteoglu, I., E. Dikicioglu, M. Erkus, N. Culhaci, F. Kacar, E. Ozkara, and M. Uyar. 2005. Breast carcinogenesis. Transition from hyperplasia to invasive lesions. *Saudi Med. J.* 26:1889–1896.

Min, K.W., D.H. Kim, S.I. Do, K. Kim, H.J. Lee, S.W. Chae, J.H. Sohn, J.S. Pyo, Y.H. Oh, W.S. Kim, et al. 2014. Expression patterns of stromal MMP-2 and tumoural MMP-2 and -9 are significant prognostic factors in invasive ductal carcinoma of the breast. *APMIS*. 122:1196–1206. http://dx.doi.org/10.1111/apm.12285

Minisini, A.M., D. Fabbro, C. Di Loreto, M. Pestrin, S. Russo, G.G. Cardellino, C. Andreetta, G. Damante, and F. Puglisi. 2007. Markers of the uPA system and common prognostic factors in breast cancer. *Am. J. Clin. Pathol.* 128:112–117. http://dx.doi.org/10.1309/M0GXVXA89BVLJ5C9

Monteagudo, C., M.J. Merino, J. San-Juan, L.A. Liotta, and W.G. Stetler-Stevenson. 1990. Immunohistochemical distribution of type IV collagenase in normal, benign, and malignant breast tissue. *Am. J. Pathol.* 136:585–592.

Mylona, E., A. Nomikos, C. Magkou, M. Kamberou, I. Papassideri, A. Keramopoulos, and L. Nakopoulou. 2007. The clinicopathological and prognostic significance of membrane type 1 matrix metalloproteinase (MT1-MMP) and MMP-9 according to their localization in invasive breast carcinoma. *Histopathology*. 50:338–347. http://dx.doi.org/10.1111/j.1365-2559.2007.02615.x

Nakopoulou, L., I. Giannopoulou, H. Gakiopoulou, H. Liapis, A. Tzonou, and P.S. Davaris. 1999. Matrix metalloproteinase-1 and -3 in breast cancer: correlation with progesterone receptors and other clinicopathologic features. *Hum. Pathol.* 30:436–442. http://dx.doi.org/10.1016/S0046-8177(99)90120-X

Nakopoulou, L., I. Tsirmpa, P. Alexandrou, A. Louvrou, C. Ampela, S. Markaki, and P.S. Davaris. 2003. MMP-2 protein in invasive breast cancer and the impact of MMP-2/TIMP-2 phenotype on overall survival. *Breast Cancer Res. Treat.* 77:145–155. http://dx.doi.org/10.1023/A:1021371028777

Nam, E., S.N. Lee, S.A. Im, D.Y. Kim, K.E. Lee, and S.H. Sung. 2005. Expression of cyclooxygenase-2 in human breast cancer: relationship with HER-2/neu and other clinicopathological prognostic factors. *Cancer Res. Treat.* 37:165–170. http://dx.doi.org/10.4143/crt.2005.37.3.165

Nielsen, B.S., F. Rank, M. Illemann, L.R. Lund, and K. Danø. 2007. Stromal cells associated with early invasive foci in human mammary ductal carcinoma in situ coexpress urokinase and urokinase receptor. *Int. J. Cancer*. 120:2086–2095. http://dx.doi.org/10.1002/ijc.22340

Nielsen, B.S., F. Rank, J.M. López, M. Balbin, F. Vizoso, L.R. Lund, K. Danø, and C. López-Otín. 2001a. Collagenase-3 expression in breast myofibroblasts as a molecular marker of transition of ductal carcinoma in situ lesions to invasive ductal carcinomas. *Cancer Res.* 61:7091–7100.

Nielsen, B.S., M. Sehested, S. Duun, F. Rank, S. Timshel, J. Rygaard, M. Johnsen, and K. Danø. 2001b. Urokinase plasminogen activator is localized in stromal cells in ductal breast cancer. *Lab. Invest.* 81:1485–1501. http://dx.doi.org/10.1038/labinvest.3780363

Nielsen, B.S., M. Sehested, S. Timshel, C. Pyke, and K. Danø. 1996. Messenger RNA for urokinase plasminogen activator is expressed in myofibroblasts adjacent to cancer cells in human breast cancer. *Lab. Invest.* 74:168–177.

Nielsen, T.O., H.N. Andrews, M. Cheang, J.E. Kucab, F.D. Hsu, J. Ragaz, C.B. Gilks, N. Makretsov, C.D. Bajdik, C. Brookes, et al. 2004. Expression of the insulin-like growth factor I receptor and urokinase plasminogen activator in breast cancer is associated with poor survival: potential for intervention with 17-allylamino geldanamycin. *Cancer Res.* 64:286–291. http://dx.doi.org/10.1158/0008-5472.CAN-03-1242

Niemiec, J., A. Adamczyk, K. Małecki, A. Ambicka, and J. Ryć. 2013. Tumor grade and matrix metalloproteinase 2 expression in stromal fibroblasts help to stratify the high-risk group of patients with early breast cancer identified on the basis of St Gallen recommendations. *Clin. Breast Cancer*. 13:119–128. http://dx.doi.org/10.1016/j.clbc.2012.12.005

Niemiec, J.A., A. Adamczyk, K. Małecki, K. Majchrzyk, and J. Ryś. 2012. Relationships between immunophenotype, Ki-67 index, microvascular density, Ep-CAM/P-cadherin, and MMP-2 expression in early-stage invasive ductal breast cancer. *Appl. Immunohistochem. Mol. Morphol.* 20:550–560. http://dx.doi.org/10.1097/PAI.0b013e31824f21af

Okada, A., J.P. Bellocq, N. Rouyer, M.P. Chenard, M.C. Rio, P. Chambon, and P. Basset. 1995. Membrane-type matrix metalloproteinase (MT-MMP) gene is expressed in stromal cells of human colon, breast, and head and neck carcinomas. *Proc. Natl. Acad. Sci. USA*. 92:2730–2734. http://dx.doi.org/10.1073/pnas.92.7.2730

Okada, Y. 2000. Tumor cell-matrix interaction: pericellular matrix degradation and metastasis. *Verh. Dtsch. Ges. Pathol.* 84:33–42.

Pacheco, M.M., M. Mourão, E.B. Mantovani, I.N. Nishimoto, and M.M. Brentani. 1998. Expression of gelatinases A and B, stromelysin-3 and matrilysin genes in breast carcinomas: clinico-pathological correlations. *Clin. Exp. Metastasis*. 16:577–585. http://dx.doi.org/10.1023/A:1006580415796

Peihong, S., and F. Perry. 2007. Expression of nm23, MMP-2, TIMP-2 in breast neoplasm in Zhengzhou Center Hospital, China. *Ethiop. Med. J.* 45:79–83.

Pellikainen, J.M., K.M. Ropponen, V.V. Kataja, J.K. Kellokoski, M.J. Eskelinen, and V.M. Kosma. 2004. Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis. *Clin. Cancer Res.* 10:7621–7628. http://dx.doi.org/10.1158/1078-0432.CCR-04-1061

Polette, M., C. Clavel, M. Cockett, S. Girod de Bentzmann, G. Murphy, and P. Birembaut. 1993. Detection and localization of mRNAs encoding matrix metalloproteinases and their tissue inhibitor in human breast pathology. *Invasion Metastasis*. 13:31–37.

Polette, M., N. Gilbert, I. Stas, B. Nawrocki, A. Nöel, A. Remacle, W.G. Stetler-Stevenson, P. Birembaut, and M. Foidart. 1994. Gelatinase A expression and localization in human breast cancers. An in situ hybridization study and immunohistochemical detection using confocal microscopy. *Virchows Arch.* 424:641–645. http://dx.doi.org/10.1007/BF01069745

Polette, M., B. Nawrocki, C. Gilles, H. Sato, M. Seiki, J.M. Tournier, and P. Birembaut. 1996. MT-MMP expression and localisation in human lung and breast cancers. *Virchows Arch.* 428:29–35. http://dx.doi.org/10.1007/BF00192924

Poulsom, R., A.M. Hanby, M. Pignatelli, R.E. Jeffery, J.M. Longcroft, L. Rogers, and G.W. Stamp. 1993. Expression of gelatinase A and TIMP-2 mRNAs in desmoplastic fibroblasts in both mammary carcinomas and basal cell carcinomas of the skin. *J. Clin. Pathol.* 46:429–436. http://dx.doi.org/10.1136/jcp.46.5.429

Rakha, E.A., M. Tun, E. Junainah, I.O. Ellis, and A. Green. 2012. Encapsulated papillary carcinoma of the breast: a study of invasion associated markers. *J. Clin. Pathol.* 65:710–714. http://dx.doi.org/10.1136/jclinpath-2012-200710

Ranogajec, I., J. Jakić-Razumović, V. Puzović, and J. Gabrilovac. 2012. Prognostic value of matrix metalloproteinase-2 (MMP-2), matrix metalloproteinase-9 (MMP-9) and aminopeptidase N/CD13 in breast cancer patients. *Med. Oncol.* 29:561–569. http://dx.doi.org/10.1007/s12032-011-9984-y

Ribeiro-Silva, A., H. Becker de Moura, F. Ribeiro do Vale, and S. Zucoloto. 2005. The differential regulation of human telomerase reverse transcriptase and vascular endothelial growth factor may contribute to the clinically more aggressive behavior of p63-positive breast carcinomas. *Int. J. Biol. Markers*. 20:227–234.

Ribeiro-Silva, A., F. Ribeiro do Vale, and S. Zucoloto. 2006. Vascular endothelial growth factor expression in the basal subtype of breast carcinoma. *Am. J. Clin. Pathol.* 125:512–518. http://dx.doi.org/10.1309/D744C4NM15J3B00D

Shah, M., D. Huang, T. Blick, A. Connor, L.A. Reiter, J.R. Hardink, C.C. Lynch, M. Waltham, and E.W. Thompson. 2012. An MMP13-selective inhibitor delays primary tumor growth and the onset of tumor-associated osteolytic lesions in experimental models of breast cancer. *PLoS ONE*. 7:e29615.

Sivula, A., A. Talvensaari-Mattila, J. Lundin, H. Joensuu, C. Haglund, A. Ristimäki, and T. Turpeenniemi-Hujanen. 2005. Association of cyclooxygenase-2 and matrix metalloproteinase-2 expression in human breast cancer. *Breast Cancer Res. Treat.* 89:215–220. http://dx.doi.org/10.1007/s10549-004-0714-4

Soini, Y., T. Hurskainen, M. Höyhtyä, A. Oikarinen, and H. Autio-Harmainen. 1994. 72 KD and 92 KD type IV collagenase, type IV collagen, and laminin mRNAs in breast cancer: a study by in situ hybridization. *J. Histochem. Cytochem.* 42:945–951. http://dx.doi.org/10.1177/42.7.8014478

Sullu, Y., G.G. Demirag, A. Yildirim, F. Karagoz, and B. Kandemir. 2011. Matrix metalloproteinase-2 (MMP-2) and MMP-9 expression in invasive ductal carcinoma of the breast. *Pathol. Res. Pract.* 207:747–753. http://dx.doi.org/10.1016/j.prp.2011.09.010

Surowiak, P., D. Murawa, V. Materna, A. Maciejczyk, M. Pudelko, S. Ciesla, J. Breborowicz, P. Murawa, M. Zabel, M. Dietel, and H. Lage. 2007. Occurence of stromal myofibroblasts in the invasive ductal breast cancer tissue is an unfavourable prognostic factor. *Anticancer Res.* 27(4C):2917–2924.

Talvensaari-Mattila, A., P. Pääkko, G. Blanco-Sequeiros, and T. Turpeenniemi-Hujanen. 2001. Matrix metalloproteinase-2 (MMP-2) is associated with the risk for a relapse in postmenopausal patients with node-positive breast carcinoma treated with antiestrogen adjuvant therapy. *Breast Cancer Res. Treat.* 65:55–61. http://dx.doi.org/10.1023/A:1006458601568

Talvensaari-Mattila, A., P. Pääkkö, M. Höyhtyä, G. Blanco-Sequeiros, and T. Turpeenniemi-Hujanen. 1998. Matrix metalloproteinase-2 immunoreactive protein: a marker of aggressiveness in breast carcinoma. *Cancer*. 83:1153–1162. http://dx.doi.org/10.1002/(SICI)1097-0142(19980915)83:6<1153::AID-CNCR14>3.0.CO;2-4

Talvensaari-Mattila, A., P. Pääkkö, and T. Turpeenniemi-Hujanen. 2003. Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma. *Br. J. Cancer*. 89:1270–1275. http://dx.doi.org/10.1038/sj.bjc.6601238

Têtu, B., J. Brisson, H. Lapointe, and P. Bernard. 1998. Prognostic significance of stromelysin 3, gelatinase A, and urokinase expression in breast cancer. *Hum. Pathol.* 29:979–985. http://dx.doi.org/10.1016/S0046-8177(98)90204-0

Têtu, B., J. Brisson, C.S. Wang, H. Lapointe, G. Beaudry, and C. Blanchette. 2001. Expression of cathepsin D, stromelysin-3, and urokinase by reactive stromal cells on breast carcinoma prognosis. *Cancer*. 92:2957–2964. http://dx.doi.org/10.1002/1097-0142(20011201)92:11<2957::AID-CNCR10112>3.0.CO;2-6

Têtu, B., J. Brisson, C.S. Wang, H. Lapointe, G. Beaudry, C. Blanchette, and D. Trudel. 2006. The influence of MMP-14, TIMP-2 and MMP-2 expression on breast cancer prognosis. *Breast Cancer Res.* 8:R28. http://dx.doi.org/10.1186/bcr1503

Ueno, H., H. Nakamura, M. Inoue, K. Imai, M. Noguchi, H. Sato, M. Seiki, and Y. Okada. 1997. Expression and tissue localization of membrane-types 1, 2, and 3 matrix metalloproteinases in human invasive breast carcinomas. *Cancer Res.* 57:2055–2060.

Umeda, T., Y. Eguchi, K. Okino, M. Kodama, and T. Hattori. 1997. Cellular localization of urokinase-type plasminogen activator, its inhibitors, and their mRNAs in breast cancer tissues. *J. Pathol.* 183:388–397. http://dx.doi.org/10.1002/(SICI)1096-9896(199712)183:4<388::AID-PATH943>3.0.CO;2-I

Uría, J.A., M. Ståhle-Bäckdahl, M. Seiki, A. Fueyo, and C. López-Otín. 1997. Regulation of collagenase-3 expression in human breast carcinomas is mediated by stromal-epithelial cell interactions. *Cancer Res.* 57:4882–4888.

Visscher, D.W., M. Höyhtyä, S.K. Ottosen, C.M. Liang, F.H. Sarkar, J.D. Crissman, and R. Fridman. 1994. Enhanced expression of tissue inhibitor of metalloproteinase-2 (TIMP-2) in the stroma of breast carcinomas correlates with tumor recurrence. *Int. J. Cancer*. 59:339–344. http://dx.doi.org/10.1002/ijc.2910590308

Vizoso, F.J., L.O. González, M.D. Corte, J.C. Rodríguez, J. Vázquez, M.L. Lamelas, S. Junquera, A.M. Merino, and J.L. García-Muñiz. 2007. Study of matrix metalloproteinases and their inhibitors in breast cancer. *Br. J. Cancer*. 96:903–911. http://dx.doi.org/10.1038/sj.bjc.6603666

Wadowska-Jaszczyćska, K., R. Jach, K. Stangel-Wócikiewicz, M. Kabzićska-Turek, P. Przybylska, A. Basta, H. Huras, G. Dyduch, M. Radoć-Pokracka, and O. Dziadek. 2011. Results in treatment of early breast cancers and the level of selected metalloproteinases. *Neuroendocrinol. Lett.* 32:821–830.

Wang, H.X., C. Qin, F.Y. Han, X.H. Wang, and N. Li. 2014. HIF-2α as a prognostic marker for breast cancer progression and patient survival. *Genet. Mol. Res.* 13:2817–2826. http://dx.doi.org/10.4238/2014.January.22.6

Wolf, C., N. Rouyer, Y. Lutz, C. Adida, M. Loriot, J.P. Bellocq, P. Chambon, and P. Basset. 1993. Stromelysin 3 belongs to a subgroup of proteinases expressed in breast carcinoma fibroblastic cells and possibly implicated in tumor progression. *Proc. Natl. Acad. Sci. USA*. 90:1843–1847. http://dx.doi.org/10.1073/pnas.90.5.1843

Xu, N., Z. Lei, X.L. Li, J. Zhang, C. Li, G.Q. Feng, D.N. Li, J.Y. Liu, Q. Wei, T.T. Bian, and T.Y. Zou. 2013. Clinical study of tumor angiogenesis and perfusion imaging using multi-slice spiral computed tomography for breast cancer. *Asian Pac. J. Cancer Prev.* 14:429–433. http://dx.doi.org/10.7314/APJCP.2013.14.1.429

Yao, G., P. He, L. Chen, X. Hu, F. Gu, and C. Ye. 2013. MT1-MMP in breast cancer: induction of VEGF-C correlates with metastasis and poor prognosis. *Cancer Cell Int.* 13:98. http://dx.doi.org/10.1186/1475-2867-13-98

Zhang, B., X. Cao, Y. Liu, W. Cao, F. Zhang, S. Zhang, H. Li, L. Ning, L. Fu, Y. Niu, et al. 2008. Tumor-derived matrix metalloproteinase-13 (MMP-13) correlates with poor prognoses of invasive breast cancer. *BMC Cancer*. 8:83. http://dx.doi.org/10.1186/1471-2407-8-83

Zhang, Y.G., J. Du, X.X. Tian, Y.F. Zhong, and W.G. Fang. 2007. Expression of E-cadherin, beta-catenin, cathepsin D, gelatinases and their inhibitors in invasive ductal breast carcinomas. *Chin. Med. J. (Engl.)*. 120:1597–1605.

Zhao, H., T. Morimoto, M. Sasa, T. Tanaka, and K. Izumi. 2002. Immunohistochemical expression of uPA, PAI-1, cathepsin D and apoptotic cells in ductal carcinoma in situ of the breast. *Breast Cancer*. 9:118–126. http://dx.doi.org/10.1007/BF02967576

Zhao, M., H.G. Hu, J. Huang, Q. Zou, J. Wang, M.Q. Liu, Y. Zhao, G.Z. Li, S. Xue, and Z.S. Wu. 2013. Expression and correlation of Twist and gelatinases in breast cancer. *Exp Ther Med*. 6:97–100.

Studies of protease localization in human colon cancer

Ahmed, M.M., and S.H. Mohammed. 2011. Matrix metalloproteinases 2 and 9 in situ mRNA expression in colorectal tumors from Iraqi patients. *Indian J. Pathol. Microbiol.* 54:7–14. http://dx.doi.org/10.4103/0377-4929.77316

Behrens, P., M. Mathiak, E. Mangold, S. Kirdorf, A. Wellmann, F. Fogt, M. Rothe, A. Florin, and N. Wernert. 2003. Stromal expression of invasion-promoting, matrix-degrading proteases MMP-1 and -9 and the Ets 1 transcription factor in HNPCC carcinomas and sporadic colorectal cancers. *Int. J. Cancer*. 107:183–188. http://dx.doi.org/10.1002/ijc.11336

Bendardaf, R., A. Buhmeida, R. Ristamäki, K. Syrjänen, and S. Pyrhönen. 2007. MMP-1 (collagenase-1) expression in primary colorectal cancer and its metastases. *Scand. J. Gastroenterol.* 42:1473–1478. http://dx.doi.org/10.1080/00365520701485449

Bendardaf, R., H. Lamlum, P. Vihinen, R. Ristamäki, J. Laine, and S. Pyrhönen. 2003. Low collagenase-1 (MMP-1) and MT1-MMP expression levels are favourable survival markers in advanced colorectal carcinoma. *Oncology*. 65:337–346. http://dx.doi.org/10.1159/000074647

Berney, C.R., R.J. Fisher, J. Yang, P.J. Russell, and P.J. Crowe. 1999. Protein markers in colorectal cancer: predictors of liver metastasis. *Ann. Surg.* 230:179–184. http://dx.doi.org/10.1097/00000658-199908000-00007

Berney, C.R., J. Yang, R.J. Fisher, P.J. Russell, and P.J. Crowe. 1998a. Correlates of urokinase-type plasminogen activator in colorectal cancer: positive relationship with nm23 and c-erbB-2 protein expression. *Oncol. Res.* 10:47–54.

Berney, C.R., J.L. Yang, R.J. Fisher, P.J. Russell, and P.J. Crowe. 1998b. Vascular endothelial growth factor expression is reduced in liver metastasis from colorectal cancer and correlates with urokinase-type plasminogen activator. *Anticancer Res.* 18(2A):973–977.

Bodey, B., B. Bodey Jr., S.E. Siegel, and H.E. Kaiser. 2000. Prognostic significance of matrix metalloproteinase expression in colorectal carcinomas. *In Vivo*. 14:659–666.

Buø, L., G.I. Meling, T.S. Karlsrud, H.T. Johansen, and A.O. Aasen. 1995. Antigen levels of urokinase plasminogen activator and its receptor at the tumor-host interface of colorectal adenocarcinomas are related to tumor aggressiveness. *Hum. Pathol.* 26:1133–1138. http://dx.doi.org/10.1016/0046-8177(95)90276-7

Burtin, P., G. Chavanel, and J. Andre. 1985. The plasmin system in human colonic tumors: an immunofluorescence study. *Int. J. Cancer*. 35:307–314. http://dx.doi.org/10.1002/ijc.2910350305

Burtin, P., G. Chavanel, J. André-Bougaran, and A. Gentile. 1987. The plasmin system in human adenocarcinomas and their metastases. A comparative immunofluorescence study. *Int. J. Cancer*. 39:170–178. http://dx.doi.org/10.1002/ijc.2910390208

Cabibi, D., A. Calascibetta, F. Aragona, A. Martorana, M. Campione, and R. Sanguedolce. 2009. Differing expression of metalloprotease and of adhesion molecules in signet-ring cell and intestinal colorectal carcinoma. *Anticancer Res.* 29:4417–4422.

Chan, C.C., M. Menges, H.D. Orzechowski, N. Orendain, G. Pistorius, G. Feifel, M. Zeitz, and A. Stallmach. 2001. Increased matrix metalloproteinase 2 concentration and transcript expression in advanced colorectal carcinomas. *Int. J. Colorectal Dis.* 16:133–140. http://dx.doi.org/10.1007/s003840100287

Cho, Y.B., W.Y. Lee, S.Y. Song, H.J. Shin, S.H. Yun, and H.K. Chun. 2007. Matrix metalloproteinase-9 activity is associated with poor prognosis in T3-T4 node-negative colorectal cancer. *Hum. Pathol.* 38:1603–1610. http://dx.doi.org/10.1016/j.humpath.2007.03.018

Collins, H.M., T.M. Morris, and S.A. Watson. 2001. Spectrum of matrix metalloproteinase expression in primary and metastatic colon cancer: relationship to the tissue inhibitors of metalloproteinases and membrane type-1-matrix metalloproteinase. *Br. J. Cancer*. 84:1664–1670. http://dx.doi.org/10.1054/bjoc.2001.1831

Curran, S., S.R. Dundas, J. Buxton, M.F. Leeman, R. Ramsay, and G.I. Murray. 2004. Matrix metalloproteinase/tissue inhibitors of matrix metalloproteinase phenotype identifies poor prognosis colorectal cancers. *Clin. Cancer Res.* 10:8229–8234. http://dx.doi.org/10.1158/1078-0432.CCR-04-0424

D'Errico, A., S. Garbisa, L.A. Liotta, V. Castronovo, W.G. Stetler-Stevenson, and W.F. Grigioni. 1991. Augmentation of type IV collagenase, laminin receptor, and Ki67 proliferation antigen associated with human colon, gastric, and breast carcinoma progression. *Mod. Pathol.* 4:239–246.

Delbaldo, C., M. Cunningham, J.D. Vassalli, and A.P. Sappino. 1995. Plasmin-catalyzed proteolysis in colorectal neoplasia. *Cancer Res.* 55:4688–4695.

Delektorskaya, V.V., A.G. Perevoshchikov, D.A. Golovkov, and N.E. Kushlinskii. 2007. Prognostic significance of expression of matrix metalloproteinase in colorectal adenocarcinomas and their metastases. *Bull. Exp. Biol. Med.* 143:455–458. http://dx.doi.org/10.1007/s10517-007-0155-2

Ferrier, C.M., H.H. de Witte, H. Straatman, D.H. van Tienoven, W.L. van Geloof, F.J. Rietveld, C.G. Sweep, D.J. Ruiter, and G.N. van Muijen. 1999. Comparison of immunohistochemistry with immunoassay (ELISA) for the detection of components of the plasminogen activation system in human tumour tissue. *Br. J. Cancer*. 79:1534–1541. http://dx.doi.org/10.1038/sj.bjc.6690245

Foda, A.A., A.K. El-Hawary, and A. Abdel-Aziz. 2013. Differential expression of matrix metalloproteinase-13 in mucinous and nonmucinous colorectal carcinomas. *Ann. Diagn. Pathol.* 17:347–351. http://dx.doi.org/10.1016/j.anndiagpath.2013.04.003

Foda, A.A., A.K. El-Hawary, and A. Abdel-Aziz. 2014. Matrix metalloproteinase-13 expression in the progression of colorectal adenoma to carcinoma. *Tumour Biol.* 35:5653–5658. http://dx.doi.org/10.1007/s13277-014-1748-9

Fujii, T., T. Obara, S. Tanno, H. Ura, and Y. Kohgo. 1999. Urokinase-type plasminogen activator and plasminogen activator inhibitor-1 as a prognostic factor in human colorectal carcinomas. *Hepatogastroenterology*. 46:2299–2308.

Gallegos, N.C., C. Smales, F.J. Savage, R.M. Hembry, and P.B. Boulos. 1995. The distribution of matrix metalloproteinases and tissue inhibitor of metalloproteinases in colorectal cancer. *Surg. Oncol.* 4:21–29. http://dx.doi.org/10.1016/S0960-7404(10)80027-1

Gomes, E.G., M.J. Jucá, H.L. de Menezes, B.L. Nunes, H. Costa, F.O. Lima, and D. Matos. 2009. Correlation between the immunohistochemical expressions of MMP-1, MMP-7 and VEGF and prognostic factors in colorectal adenocarcinoma. *Acta Cir. Bras.* 24:303–310. http://dx.doi.org/10.1590/S0102-86502009000400010

González, L., N. Eiró, L.O. González, A. Andicoechea, E. Barbón, J.L. García-Muñiz, and F.J. Vizoso. 2012. Effect of the expression of matrix metalloproteases and their tissue inhibitors on survival of patients with resectable colorectal cancer. *Dig. Dis. Sci.* 57:2063–2071. http://dx.doi.org/10.1007/s10620-012-2154-z

Gray, S.T., K. Yun, T. Motoori, and Y.M. Kuys. 1993. Interstitial collagenase gene expression in colonic neoplasia. *Am. J. Pathol.* 143:663–671.

Grigioni, W.F., A. D'Errico, M. Fiorentino, P. Baccarini, M. Onisto, C. Caenazzo, W.G. Stetler-Stevenson, S. Garbisa, and A.M. Mancini. 1994. Gelatinase A (MMP-2) and its mRNA detected in both neoplastic and stromal cells of tumors with different invasive and metastatic properties. *Diagn. Mol. Pathol.* 3:163–169. http://dx.doi.org/10.1097/00019606-199409000-00005

Groblewska, M., B. Mroczko, M. Gryko, A. Pryczynicz, K. Guzińska-Ustymowicz, B. Kćdra, A. Kemona, and M. Szmitkowski. 2014. Serum levels and tissue expression of matrix metalloproteinase 2 (MMP-2) and tissue inhibitor of metalloproteinases 2 (TIMP-2) in colorectal cancer patients. *Tumour Biol.* 35:3793–3802. http://dx.doi.org/10.1007/s13277-013-1502-8

Grøndahl-Hansen, J., E. Ralfkiaer, L.T. Kirkeby, P. Kristensen, L.R. Lund, and K. Danø. 1991. Localization of urokinase-type plasminogen activator in stromal cells in adenocarcinomas of the colon in humans. *Am. J. Pathol.* 138:111–117.

Guo, H., A. Tatsuguchi, S. Shinji, S. Fujimori, S. Tanaka, K. Gudis, Y. Sugisaki, K. Furukawa, T. Tajiri, Y. Fukuda, et al. 2006. Cyclooxygenase-2 expression correlates with membrane-type-1 matrix metalloproteinase expression in colorectal cancer tissue. *Dis. Colon Rectum*. 49:1184–1192. http://dx.doi.org/10.1007/s10350-006-0588-0

Harvey, S., S. Kohga, S.N. Sait, G. Markus, T.C. Hurd, M. Martinick, J. Geradts, R. Saxena, and J.F. Gibbs. 2009. Co-expression of urokinase with haptoglobin in human carcinomas. *J. Surg. Res.* 152:189–197. http://dx.doi.org/10.1016/j.jss.2008.06.016

Harvey, S.R., S.N. Sait, Y. Xu, J.L. Bailey, R.M. Penetrante, and G. Markus. 1999. Demonstration of urokinase expression in cancer cells of colon adenocarcinomas by immunohistochemistry and in situ hybridization. *Am. J. Pathol.* 155:1115–1120. http://dx.doi.org/10.1016/S0002-9440(10)65214-5

Hiendlmeyer, E., S. Regus, S. Wassermann, F. Hlubek, A. Haynl, A. Dimmler, C. Koch, C. Knoll, M. van Beest, U. Reuning, et al. 2004. Beta-catenin up-regulates the expression of the urokinase plasminogen activator in human colorectal tumors. *Cancer Res.* 64:1209–1214. http://dx.doi.org/10.1158/0008-5472.CAN-3627-2

Hilska, M., P.J. Roberts, Y.U. Collan, V.J. Laine, J. Kössi, P. Hirsimäki, O. Rahkonen, and M. Laato. 2007. Prognostic significance of matrix metalloproteinases-1, -2, -7 and -13 and tissue inhibitors of metalloproteinases-1, -2, -3 and -4 in colorectal cancer. *Int. J. Cancer*. 121:714–723. http://dx.doi.org/10.1002/ijc.22747

Hong, S.W., Y.K. Kang, B. Lee, W.Y. Lee, Y.G. Jang, I.W. Paik, and H. Lee. 2011. Matrix metalloproteinase-2 and -7 expression in colorectal cancer. *J Korean Soc Coloproctol*. 27:133–139. http://dx.doi.org/10.3393/jksc.2011.27.3.133

Huang, M.Y., H.J. Chang, F.Y. Chung, M.J. Yang, Y.H. Yang, J.Y. Wang, and S.R. Lin. 2010. MMP13 is a potential prognostic marker for colorectal cancer. *Oncol. Rep.* 24:1241–1247.

Illemann, M., N. Bird, A. Majeed, O.D. Laerum, L.R. Lund, K. Danø, and B.S. Nielsen. 2009. Two distinct expression patterns of urokinase, urokinase receptor and plasminogen activator inhibitor-1 in colon cancer liver metastases. *Int. J. Cancer*. 124:1860–1870. http://dx.doi.org/10.1002/ijc.24166

Inafuku, Y., T. Furuhata, M. Tayama, K. Okita, T. Nishidate, T. Mizuguchi, Y. Kimura, and K. Hirata. 2009. Matrix metalloproteinase-2 expression in stromal tissues is a consistent prognostic factor in stage II colon cancer. *Cancer Sci.* 100:852–858. http://dx.doi.org/10.1111/j.1349-7006.2009.01116.x

Inuzuka, K., Y. Ogata, H. Nagase, and K. Shirouzu. 2000. Significance of coexpression of urokinase-type plasminogen activator, and matrix metalloproteinase 3 (stromelysin) and 9 (gelatinase B) in colorectal carcinoma. *J. Surg. Res.* 93:211–218. http://dx.doi.org/10.1006/jsre.2000.5952

Jeffery, N., M.H. McLean, E.M. El-Omar, and G.I. Murray. 2009. The matrix metalloproteinase/tissue inhibitor of matrix metalloproteinase profile in colorectal polyp cancers. *Histopathology*. 54:820–828. http://dx.doi.org/10.1111/j.1365-2559.2009.03301.x

Kang, J.C., J.S. Chen, C.H. Lee, J.J. Chang, and Y.S. Shieh. 2010. Intratumoral macrophage counts correlate with tumor progression in colorectal cancer. *J. Surg. Oncol.* 102:242–248. http://dx.doi.org/10.1002/jso.21617

Kawanishi, H., K. Tanaka, S. Takai, H. Takada, M. Yamamura, K. Hioki, H. Nagura, and M. Yamamoto. 1991. Immunohistochemical analysis of plasminogen activator expression in human colorectal carcinomas: correlation with CEA distribution and tumor cell kinetics. *J. Surg. Oncol.* 46:246–256. http://dx.doi.org/10.1002/jso.2930460408

Kikuchi, R., T. Noguchi, S. Takeno, N. Kubo, and Y. Uchida. 2000. Immunohistochemical detection of membrane-type-1-matrix metalloproteinase in colorectal carcinoma. *Br. J. Cancer*. 83:215–218.

Kim, S.J., E. Shiba, F. Tsukamoto, M. Izukura, T. Taguchi, K. Yoneda, Y. Tanji, Y. Kimoto, and S.I. Takai. 1998. The expression of urokinase type plasminogen activator is a novel prognostic factor in dukes B and C colorectal cancer. *Oncol. Rep.* 5:431–435.

Kim, T.S., and Y.B. Kim. 1999. Correlation between expression of matrix metalloproteinase-2 (MMP-2), and matrix metalloproteinase-9 (MMP-9) and angiogenesis in colorectal adenocarcinoma. *J. Korean Med. Sci.* 14:263–270. http://dx.doi.org/10.3346/jkms.1999.14.3.263

Kim, Y.W., Y.T. Ko, N.K. Kim, H.C. Chung, B.S. Min, K.Y. Lee, J.P. Park, and H. Kim. 2010. A comparative study of protein expression in primary colorectal cancer and synchronous hepatic metastases: the significance of matrix metalloproteinase-1 expression as a predictor of liver metastasis. *Scand. J. Gastroenterol.* 45:217–225. http://dx.doi.org/10.3109/00365520903453158

Kitadai, Y., L.M. Ellis, Y. Takahashi, C.D. Bucana, H. Anzai, E. Tahara, and I.J. Fidler. 1995. Multiparametric in situ messenger RNA hybridization analysis to detect metastasis-related genes in surgical specimens of human colon carcinomas. *Clin. Cancer Res.* 1:1095–1102.

Kitadai, Y., L.M. Ellis, S.L. Tucker, G.F. Greene, C.D. Bucana, K.R. Cleary, Y. Takahashi, E. Tahara, and I.J. Fidler. 1996. Multiparametric in situ mRNA hybridization analysis to predict disease recurrence in patients with colon carcinoma. *Am. J. Pathol.* 149:1541–1551.

Klinge, U., R. Rosch, K. Junge, C.J. Krones, M. Stumpf, P. Lynen-Jansen, P.R. Mertens, and V. Schumpelick. 2007. Different matrix micro-environments in colon cancer and diverticular disease. *Int. J. Colorectal Dis.* 22:515–520. http://dx.doi.org/10.1007/s00384-006-0199-1

Kohga, S., S.R. Harvey, R.M. Weaver, and G. Markus. 1985. Localization of plasminogen activators in human colon cancer by immunoperoxidase staining. *Cancer Res.* 45:1787–1796.

Koretz, K., P. Möller, and R. Schwartz-Albiez. 1993. Plasminogen activators and plasminogen activator inhibitors in human colorectal carcinoma tissues are not expressed by the tumour cells. *Eur. J. Cancer*. 29A:1184–1189.

Koskensalo, S., J. Hagström, N. Linder, M. Lundin, T. Sorsa, J. Louhimo, and C. Haglund. 2012. Lack of MMP-9 expression is a marker for poor prognosis in Dukes' B colorectal cancer. *BMC Clin. Pathol.* 12:24. http://dx.doi.org/10.1186/1472-6890-12-24

Lee, S.W., Y.Y. Ahn, Y.S. Kim, S.B. Kang, S.W. Nam, D.S. Lee, H.Y. Jeong, and J.M. Kim. 2012. The Immunohistochemical Expression of STAT3, Bcl-xL, and MMP-2 Proteins in Colon Adenoma and Adenocarcinoma. *Gut Liver*. 6:45–51. http://dx.doi.org/10.5009/gnl.2012.6.1.45

Leeman, M.F., J.A. McKay, and G.I. Murray. 2002. Matrix metalloproteinase 13 activity is associated with poor prognosis in colorectal cancer. *J. Clin. Pathol.* 55:758–762. http://dx.doi.org/10.1136/jcp.55.10.758

Levy, A.T., V. Cioce, M.E. Sobel, S. Garbisa, W.F. Grigioni, L.A. Liotta, and W.G. Stetler-Stevenson. 1991. Increased expression of the Mr 72,000 type IV collagenase in human colonic adenocarcinoma. *Cancer Res.* 51:439–444.

Li, B.H., P. Zhao, S.Z. Liu, Y.M. Yu, M. Han, and J.K. Wen. 2005a. Matrix metalloproteinase-2 and tissue inhibitor of metallo-proteinase-2 in colorectal carcinoma invasion and metastasis. *World J. Gastroenterol.* 11:3046–3050. http://dx.doi.org/10.3748/wjg.v11.i20.3046

Li, L., Y.H. Huang, Y. Li, F.Q. Wang, B.Y. Shang, and Y.S. Zhen. 2005b. Antitumor activity of anti-type IV collagenase monoclonal antibody and its lidamycin conjugate against colon carcinoma. *World J. Gastroenterol.* 11:4478–4483.

Li, M., J.Y. Li, A.L. Zhao, and J. Gu. 2007a. Colorectal cancer or colon and rectal cancer? Clinicopathological comparison between colonic and rectal carcinomas. *Oncology*. 73:52–57. http://dx.doi.org/10.1159/000120628

Li, M., J.Y. Li, A.L. Zhao, and J. Gu. 2011. Do young patients with colorectal cancer have a poorer prognosis than old patients? *J. Surg. Res.* 167:231–236. http://dx.doi.org/10.1016/j.jss.2010.10.040

Li, M., J.Y. Li, A.L. Zhao, J.S. He, L.X. Zhou, Y.A. Li, and J. Gu. 2007b. Survival stratification panel of colorectal carcinoma with combined expression of carcinoembryonic antigen, matrix metalloproteinases-2, and p27 kip1. *Dis. Colon Rectum*. 50:1887–1898. http://dx.doi.org/10.1007/s10350-007-9053-y

Lustosa, S.A., L.S. Viana, R.J. Affonso Jr., S.R. Silva, M.V. Denadai, S.R. de Toledo, I.D. Oliveira, and D. Matos. 2014. Expression profiling using a cDNA array and immunohistochemistry for the extracellular matrix genes FN-1, ITGA-3, ITGB-5, MMP-2, and MMP-9 in colorectal carcinoma progression and dissemination. *ScientificWorldJournal*. 2014:102541. http://dx.doi.org/10.1155/2014/102541

Lyall, M.S., S.R. Dundas, S. Curran, and G.I. Murray. 2006. Profiling markers of prognosis in colorectal cancer. *Clin. Cancer Res.* 12:1184–1191. http://dx.doi.org/10.1158/1078-0432.CCR-05-1864

Masaki, T., M. Sugiyama, H. Matsuoka, N. Abe, Y. Izumisato, A. Sakamoto, and Y. Atomi. 2003. Matrix metalloproteinases may contribute compensationally to tumor invasion in T1 colorectal carcinomas. *Anticancer Res.* 23(5b):4169–4173.

Masaki, T., M. Sugiyama, H. Matsuoka, N. Abe, Y. Izumisato, A. Sakamoto, and Y. Atomi. 2003. Matrix metalloproteinases may contribute compensationally to tumor invasion in T1 colorectal carcinomas. *Anticancer Res.* 23(5b):4169–4173.

Minoo, P., K. Baker, D. Baumhoer, L. Terracciano, A. Lugli, and I. Zlobec. 2010. Urokinase-type plasminogen activator is a marker of aggressive phenotype and an independent prognostic factor in mismatch repair-proficient colorectal cancer. *Hum. Pathol.* 41:70–78. http://dx.doi.org/10.1016/j.humpath.2009.05.013

Mori, D., Y. Nakafusa, K. Miyazaki, and O. Tokunaga. 2005. Differential expression of Janus kinase 3 (JAK3), matrix metalloproteinase 13 (MMP13), heat shock protein 60 (HSP60), and mouse double minute 2 (MDM2) in human colorectal cancer progression using human cancer cDNA microarrays. *Pathol. Res. Pract.* 201:777–789. http://dx.doi.org/10.1016/j.prp.2005.06.005

Mukai, M., S. Sadahiro, N. Tokunaga, K. Ishizu, I. Ito, T. Kameya, K. Ishikawa, H. Iwase, T. Suzuki, H. Ishida, et al. 1999. The expression of MMP-2 and TIMP-2 in patients with primary colorectal adenocarcinoma: correlation with liver metastasis. *Oncol. Rep.* 6:969–973.

Mukai, M., S. Sadahiro, N. Tokunaga, K. Ishizu, I. Ito, T. Kameya, K. Ishikawa, H. Iwase, T. Suzuki, T. Kimura, et al. 1998. The expression of MMP-2 and TIMP-2 in patients with colorectal adenocarcinoma invaded to the submucosal and proper muscle layer. *Oncol. Rep.* 5:335–340.

Mulcahy, H.E., M.J. Duffy, D. Gibbons, P. McCarthy, N.A. Parfrey, D.P. O'Donoghue, and K. Sheahan. 1994. Urokinase-type plasminogen activator and outcome in Dukes' B colorectal cancer. *Lancet*. 344:583–584. http://dx.doi.org/10.1016/S0140-6736(94)91968-2

Murai, S., T. Umemiya, M. Seiki, and K. Harigaya. 2004. Expression and localization of membrane-type-1 matrix metalloproteinase, CD 44, and laminin-5γ2 chain during colorectal carcinoma tumor progression. *Virchows Arch.* 445:271–278. http://dx.doi.org/10.1007/s00428-004-1029-x

Murray, G.I., M.E. Duncan, P. O'Neil, W.T. Melvin, and J.E. Fothergill. 1996. Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. *Nat. Med.* 2:461–462. http://dx.doi.org/10.1038/nm0496-461

Naitoh, H., Y. Eguchi, H. Ueyama, M. Kodama, and T. Hattori. 1995. Localization of urokinase-type plasminogen activator, plasminogen activator inhibitor-1, 2 and plasminogen in colon cancer. *Jpn. J. Cancer Res.* 86:48–56. http://dx.doi.org/10.1111/j.1349-7006.1995.tb02987.x

Newell, K.J., J.P. Witty, W.H. Rodgers, and L.M. Matrisian. 1994. Expression and localization of matrix-degrading metalloproteinases during colorectal tumorigenesis. *Mol. Carcinog.* 10:199–206. http://dx.doi.org/10.1002/mc.2940100404

Ngan, C.Y., H. Yamamoto, I. Seshimo, K. Ezumi, M. Terayama, H. Hemmi, I. Takemasa, M. Ikeda, M. Sekimoto, and M. Monden. 2007. A multivariate analysis of adhesion molecules expression in assessment of colorectal cancer. *J. Surg. Oncol.* 95:652–662. http://dx.doi.org/10.1002/jso.20638

Nunes, B.L., M.J. Jucá, E.G. Gomes, H.L. Menezes, H.O. Costa, D. Matos, and S.S. Saad. 2009. Metalloproteinase-1, metalloproteinase-7, and p53 immunoexpression and their correlation with clinicopathological prognostic factors in colorectal adenocarcinoma. *Int. J. Biol. Markers*. 24:156–164.

Obermeyer, K., S. Krueger, B. Peters, B. Falkenberg, A. Roessner, and C. Röcken. 2007. The expression of low density lipoprotein receptor-related protein in colorectal carcinoma. *Oncol. Rep.* 17:361–367.

Ogura, E., H. Senzaki, Y. Kiyozuka, H. Takada, K. Hioki, and A. Tsubura. 1997. Expression and localization of matrix metalloproteinases and tissue inhibitors of metalloproteinases as a prognostic factor in advanced colorectal carcinomas. *Oncol. Rep.* 4:701–705.

Ohtani, H., H. Motohashi, H. Sato, M. Seiki, and H. Nagura. 1996. Dual over-expression pattern of membrane-type metalloproteinase-1 in cancer and stromal cells in human gastrointestinal carcinoma revealed by in situ hybridization and immunoelectron microscopy. *Int. J. Cancer*. 68:565–570. http://dx.doi.org/10.1002/(SICI)1097-0215(19961127)68:5<565::AID-IJC2>3.0.CO;2-X

Ohtani, H., T. Nagai, and H. Nagura. 1995. Similarities of in situ mRNA expression between gelatinase A (MMP-2) and type I procollagen in human gastrointestinal carcinoma: comparison with granulation tissue reaction. *Jpn. J. Cancer Res.* 86:833–839. http://dx.doi.org/10.1111/j.1349-7006.1995.tb03093.x

Okada, A., J.P. Bellocq, N. Rouyer, M.P. Chenard, M.C. Rio, P. Chambon, and P. Basset. 1995. Membrane-type matrix metalloproteinase (MT-MMP) gene is expressed in stromal cells of human colon, breast, and head and neck carcinomas. *Proc. Natl. Acad. Sci. USA*. 92:2730–2734. http://dx.doi.org/10.1073/pnas.92.7.2730

Omran, O.M., and M. Thabet. 2012. Gelatinases A and B expression in human colorectal cancer in upper Egypt: a clinicopathological study. *Ultrastruct. Pathol.* 36:108–116. http://dx.doi.org/10.3109/01913123.2011.641671

Otani, Y., I. Okazaki, M. Arai, K. Kameyama, N. Wada, K. Maruyama, K. Yoshino, M. Kitajima, Y. Hosoda, and M. Tsuchiya. 1994. Gene expression of interstitial collagenase (matrix metalloproteinase 1) in gastrointestinal tract cancers. *J. Gastroenterol.* 29:391–397. http://dx.doi.org/10.1007/BF02361233

Papadopoulou, S., A. Scorilas, N. Arnogianaki, B. Papapanayiotou, A. Tzimogiani, N. Agnantis, and M. Talieri. 2001. Expression of gelatinase-A (MMP-2) in human colon cancer and normal colon mucosa. *Tumour Biol.* 22:383–389. http://dx.doi.org/10.1159/000050641

Papadopoulou, S., A. Scorilas, J. Yotis, N. Arnogianaki, G. Plataniotis, N. Agnanti, and M. Talieri. 2002. Significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 (PAI-1) expression in human colorectal carcinomas. *Tumour Biol.* 23:170–178. http://dx.doi.org/10.1159/000064033

Peng, Z.H., D.S. Wan, L.R. Li, G. Chen, Z.H. Lu, X.J. Wu, L.H. Kong, and Z.Z. Pan. 2011. Expression of COX-2, MMP-2 and VEGF in stage II and III colorectal cancer and the clinical significance. *Hepatogastroenterology*. 58:369–376.

Pyke, C., P. Kristensen, E. Ralfkiaer, J. Grøndahl-Hansen, J. Eriksen, F. Blasi, and K. Danø. 1991. Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. *Am. J. Pathol.* 138:1059–1067.

Pyke, C., E. Ralfkiaer, K. Tryggvason, and K. Danø. 1993. Messenger RNA for two type IV collagenases is located in stromal cells in human colon cancer. *Am. J. Pathol.* 142:359–365.

Qian, L.Y., P. Li, X.R. Li, D.J. Chen, and S.H. Zhu. 2012. Multivariate analysis of molecular indicators for postoperative liver metastasis in colorectal cancer cases. *Asian Pac. J. Cancer Prev.* 13:3967–3971. http://dx.doi.org/10.7314/APJCP.2012.13.8.3967

Richter, K.K., L.M. Fink, B.M. Hughes, H.M. Shmaysani, C.C. Sung, and M. Hauer-Jensen. 1998. Differential effect of radiation on endothelial cell function in rectal cancer and normal rectum. *Am. J. Surg.* 176:642–647. http://dx.doi.org/10.1016/S0002-9610(98)00280-3

Ring, P., K. Johansson, M. Höyhtyä, K. Rubin, and G. Lindmark. 1997. Expression of tissue inhibitor of metalloproteinases TIMP-2 in human colorectal cancer—a predictor of tumour stage. *Br. J. Cancer*. 76:805–811. http://dx.doi.org/10.1038/bjc.1997.466

Schwandner, O., A. Schlamp, R. Broll, and H.P. Bruch. 2007. Clinicopathologic and prognostic significance of matrix metalloproteinases in rectal cancer. *Int. J. Colorectal Dis.* 22:127–136. http://dx.doi.org/10.1007/s00384-006-0173-y

Seetoo, D.Q., P.J. Crowe, P.J. Russell, and J.L. Yang. 2003. Quantitative expression of protein markers of plasminogen activation system in prognosis of colorectal cancer. *J. Surg. Oncol.* 82:184–193. http://dx.doi.org/10.1002/jso.10210

Shiozawa, J., M. Ito, T. Nakayama, M. Nakashima, S. Kohno, and I. Sekine. 2000. Expression of matrix metalloproteinase-1 in human colorectal carcinoma. *Mod. Pathol.* 13:925–933. http://dx.doi.org/10.1038/modpathol.3880169

Sier, C.F., C. Fellbaum, H.W. Verspaget, M. Schmitt, G. Griffioen, H. Graeff, H. Hôfler, and C.B. Lamers. 1991. Immunolocalization of urokinase-type plasminogen activator in adenomas and carcinomas of the colorectum. *Histopathology*. 19:231–238. http://dx.doi.org/10.1111/j.1365-2559.1991.tb00027.x

Sis, B., O. Saćol, A. Küpelioćlu, S. Sokmen, C. Terzi, M. Fuzun, E. Ozer, and P. Bishop. 2004. Prognostic significance of matrix metalloproteinase-2, cathepsin D, and tenascin-C expression in colorectal carcinoma. *Pathol. Res. Pract.* 200:379–387. http://dx.doi.org/10.1016/j.prp.2004.02.012

Sordat, I., P. Chaubert, P. Protiva, L. Guillou, L. Mazzucchelli, E. Saraga, J. Benhattar, C. Trân-Thang, A.L. Blum, G. Dorta, and B. Sordat. 1997. In situ stromal expression of the urokinase/plasmin system correlates with epithelial dysplasia in colorectal adenomas. *Am. J. Pathol.* 150:283–295.

Sunami, E., N. Tsuno, T. Osada, S. Saito, J. Kitayama, S. Tomozawa, T. Tsuruo, Y. Shibata, T. Muto, and H. Nagawa. 2000. MMP-1 is a prognostic marker for hematogenous metastasis of colorectal cancer. *Oncologist*. 5:108–114. http://dx.doi.org/10.1634/theoncologist.5-2-108

Šundov, Z., S. Tomić, K. Vilović, N. Kunac, M. Kalebić, and J. Bezić. 2008. Immunohistochemically detected high expression of matrix metalloproteinase-2 as predictor of poor prognosis in Duke's B colon cancer. *Croat. Med. J.* 49:636–642. http://dx.doi.org/10.3325/cmj.2008.5.636

Svagzdys, S., V. Lesauskaite, D. Pangonyte, Z. Saladzinskas, A. Tamelis, and D. Pavalkis. 2011. Matrix metalloproteinase-9 is a prognostic marker to predict survival of patients who underwent surgery due to rectal carcinoma. *Tohoku J. Exp. Med.* 223:67–73. http://dx.doi.org/10.1620/tjem.223.67

Takeha, S., Y. Fujiyama, T. Bamba, T. Sorsa, H. Nagura, and H. Ohtani. 1997. Stromal expression of MMP-9 and urokinase receptor is inversely associated with liver metastasis and with infiltrating growth in human colorectal cancer: a novel approach from immune/inflammatory aspect. *Jpn. J. Cancer Res.* 88:72–81. http://dx.doi.org/10.1111/j.1349-7006.1997.tb00304.x

Tatsuta, S., S. Tanaka, K. Haruma, M. Yoshihara, K. Sumii, G. Kajiyama, and F. Shimamoto. 1997. Combined expression of urokinase-type plasminogen activator and proliferating cell nuclear antigen at the deepest invasive portion correlates with colorectal cancer prognosis. *Int. J. Oncol.* 10:125–129.

Tutton, M.G., M.L. George, S.A. Eccles, S. Burton, R.I. Swift, and A.M. Abulafi. 2003. Use of plasma MMP-2 and MMP-9 levels as a surrogate for tumour expression in colorectal cancer patients. *Int. J. Cancer*. 107:541–550. http://dx.doi.org/10.1002/ijc.11436

Unsal, D., N. Akyurek, A. Uner, O.P. Erpolat, U. Han, M. Akmansu, B.B. Mentes, and A. Dursun. 2008. Gelatinase B expression as a prognostic factor in patients with stage II/III rectal carcinoma treated by postoperative adjuvant therapy. *Am. J. Clin. Oncol.* 31:55–63. http://dx.doi.org/10.1097/COC.0b013e318068b4e2

Unsal Kilic, D., A. Uner, N. Akyurek, P. Erpolat, A. Dursun, and Y. Pak. 2007. Matrix metalloproteinase-9 expression correlated with tumor response in patients with locally advanced rectal cancer undergoing preoperative chemoradiotherapy. *Int. J. Radiat. Oncol. Biol. Phys.* 67:196–203. http://dx.doi.org/10.1016/j.ijrobp.2006.08.010

Wong, J.C., S.K. Chan, D.F. Schaeffer, X. Sagaert, H.J. Lim, H. Kennecke, D.A. Owen, K.W. Suh, Y.B. Kim, and I.T. Tai. 2011. Absence of MMP2 expression correlates with poor clinical outcomes in rectal cancer, and is distinct from MMP1-related outcomes in colon cancer. *Clin. Cancer Res.* 17:4167–4176. http://dx.doi.org/10.1158/1078-0432.CCR-10-1224

Xiong, B., T.J. Sun, W.D. Hu, F.L. Cheng, M. Mao, and Y.F. Zhou. 2005. Expression of cyclooxygenase-2 in colorectal cancer and its clinical significance. *World J. Gastroenterol.* 11:1105–1108. http://dx.doi.org/10.3748/wjg.v11.i8.1105

Yang, B., J. Gao, Z. Rao, and Q. Shen. 2012. Clinicopathological significance and prognostic value of MMP-13 expression in colorectal cancer. *Scand. J. Clin. Lab. Invest.* 72:501–505. http://dx.doi.org/10.3109/00365513.2012.699638

Yang, J.L., D. Seetoo, Y. Wang, M. Ranson, C.R. Berney, J.M. Ham, P.J. Russell, and P.J. Crowe. 2000. Urokinase-type plasminogen activator and its receptor in colorectal cancer: independent prognostic factors of metastasis and cancer-specific survival and potential therapeutic targets. *Int. J. Cancer*. 89:431–439. http://dx.doi.org/10.1002/1097-0215(20000920)89:5<431::AID-IJC6>3.0.CO;2-V

Zlobec, I., S. Höller, L. Tornillo, L. Terracciano, and A. Lugli. 2009. Combined histomorphologic and immunohistochemical phenotype to predict the presence of vascular invasion in colon cancer. *Dis. Colon Rectum*. 52:1114–1121. http://dx.doi.org/10.1007/DCR.0b013e31819eefd9

Zlobec, I., P. Minoo, D. Baumhoer, K. Baker, L. Terracciano, J.R. Jass, and A. Lugli. 2008a. Multimarker phenotype predicts adverse survival in patients with lymph node-negative colorectal cancer. *Cancer*. 112:495–502. http://dx.doi.org/10.1002/cncr.23208

Zlobec, I., L. Terracciano, L. Tornillo, U. Günthert, T. Vuong, J.R. Jass, and A. Lugli. 2008b. Role of RHAMM within the hierarchy of well-established prognostic factors in colorectal cancer. *Gut*. 57:1413–1419. http://dx.doi.org/10.1136/gut.2007.141192

Studies of protease localization in human lung cancer

Aljada, I.S., N. Ramnath, K. Donohue, S. Harvey, J.J. Brooks, S.M. Wiseman, T. Khoury, G. Loewen, H.K. Slocum, T.M. Anderson, et al. 2004. Upregulation of the tissue inhibitor of metalloproteinase-1 protein is associated with progression of human non-small-cell lung cancer. *J. Clin. Oncol.* 22:3218–3229. http://dx.doi.org/10.1200/JCO.2004.02.110

Bolon, I., M. Devouassoux, C. Robert, D. Moro, C. Brambilla, and E. Brambilla. 1997. Expression of urokinase-type plasminogen activator, stromelysin 1, stromelysin 3, and matrilysin genes in lung carcinomas. *Am. J. Pathol.* 150:1619–1629.

Bolon, I., V. Gouyer, M. Devouassoux, B. Vandenbunder, N. Wernert, D. Moro, C. Brambilla, and E. Brambilla. 1995. Expression of c-ets-1, collagenase 1, and urokinase-type plasminogen activator genes in lung carcinomas. *Am. J. Pathol.* 147:1298–1310.

Byun, J.H., M.A. Lee, S.Y. Roh, B.Y. Shim, S.H. Hong, Y.H. Ko, S.J. Ko, I.S. Woo, J.H. Kang, Y.S. Hong, et al. 2006. Association between cyclooxygenase-2 and matrix metalloproteinase-2 expression in non-small cell lung cancer. *Jpn. J. Clin. Oncol.* 36:263–268. http://dx.doi.org/10.1093/jjco/hyl024

Cox, G., J.L. Jones, A. Andi, D.A. Waller, and K.J. O'Byrne. 2001. A biological staging model for operable non-small cell lung cancer. *Thorax*. 56:561–566. http://dx.doi.org/10.1136/thorax.56.7.561

D'Amico, T.A., T.A. Aloia, M.B. Moore, D.H. Conlon, J.E. Herndon II, M.S. Kinch, and D.H. Harpole Jr. 2001. Predicting the sites of metastases from lung cancer using molecular biologic markers. *Ann. Thorac. Surg.* 72:1144–1148. http://dx.doi.org/10.1016/S0003-4975(01)02979-4

Dong, B., M. Sato, A. Sakurada, M. Sagawa, C. Endo, S. Wu, S. Yamanaka, A. Horii, and T. Kondo. 2005. Computed tomographic images reflect the biologic behavior of small lung adenocarcinoma: they correlate with cell proliferation, microvascularization, cell adhesion, degradation of extracellular matrix, and K-ras mutation. *J. Thorac. Cardiovasc. Surg.* 130:733–739. http://dx.doi.org/10.1016/j.jtcvs.2005.05.013

Fan, J., F.Y. Wu, L. Wang, G.N. Jiang, and W. Gao. 2011. Comparative expression of matrix metalloproteinases in low-grade mucoepidermoid carcinoma and typical lung cancer. *Oncol. Lett.* 2:1269–1273.

Frey, A.B., A. Wali, H. Pass, and F. Lonardo. 2007. Osteopontin is linked to p65 and MMP-9 expression in pulmonary adenocarcinoma but not in malignant pleural mesothelioma. *Histopathology*. 50:720–726. http://dx.doi.org/10.1111/j.1365-2559.2007.02675.x

Gaeta, M., A. Blandino, S. Pergolizzi, S. Mazziotti, R. Caruso, M. Barone, and S. Cascinu. 2003. Patterns of recurrence of bronchioloalveolar cell carcinoma after surgical resection: a radiological, histological, and immunohistochemical study. *Lung Cancer*. 42:319–326. http://dx.doi.org/10.1016/S0169-5002(03)00362-3

Galateau-Salle, F.B., R.E. Luna, K. Horiba, M.N. Sheppard, T. Hayashi, M.V. Fleming, T.V. Colby, W. Bennett, C.C. Harris, W.G. Stetler-Stevenson, et al. 2000. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in bronchial squamous preinvasive lesions. *Hum. Pathol.* 31:296–305. http://dx.doi.org/10.1016/S0046-8177(00)80242-7

Grossi, F., R. Spizzo, D. Bordo, V. Cacitti, F. Valent, C. Rossetto, A. Follador, S. Di Terlizzi, M. Aita, A. Morelli, et al. 2010. Prognostic stratification of stage IIIA pN2 non-small cell lung cancer by hierarchical clustering analysis of tissue microarray immunostaining data: an Alpe Adria Thoracic Oncology Multidisciplinary Group study (ATOM 014). *J. Thorac. Oncol.* 5:1354–1360. http://dx.doi.org/10.1097/JTO.0b013e3181e77a78

Guo, C.B., S. Wang, C. Deng, D.L. Zhang, F.L. Wang, and X.Q. Jin. 2007. Relationship between matrix metalloproteinase 2 and lung cancer progression. *Mol. Diagn. Ther.* 11:183–192. http://dx.doi.org/10.1007/BF03256240

Herbst, R.S., S. Yano, H. Kuniyasu, F.R. Khuri, C.D. Bucana, F. Guo, D. Liu, B. Kemp, J.J. Lee, W.K. Hong, and I.J. Fidler. 2000. Differential expression of E-cadherin and type IV collagenase genes predicts outcome in patients with stage I non-small cell lung carcinoma. *Clin. Cancer Res.* 6:790–797.

Hoikkala, S., P. Pääkkö, Y. Soini, R. Mäkitaro, V. Kinnula, and T. Turpeenniemi-Hujanen. 2006. Tissue MMP-2 and MMP-9 [corrected] are better prognostic factors than serum MMP-2/TIMP-2—complex or TIMP-1 [corrected] in stage [corrected] I-III lung carcinoma. *Cancer Lett.* 236:125–132. http://dx.doi.org/10.1016/j.canlet.2005.05.012

Iizasa, T., T. Fujisawa, M. Suzuki, S. Motohashi, K. Yasufuku, T. Yasukawa, M. Baba, and M. Shiba. 1999. Elevated levels of circulating plasma matrix metalloproteinase 9 in non-small cell lung cancer patients. *Clin. Cancer Res.* 5:149–153.

Ishikawa, S., K. Takenaka, K. Yanagihara, R. Miyahara, Y. Kawano, Y. Otake, S. Hasegawa, H. Wada, and F. Tanaka. 2004. Matrix metalloproteinase-2 status in stromal fibroblasts, not in tumor cells, is a significant prognostic factor in non-small-cell lung cancer. *Clin. Cancer Res.* 10:6579–6585. http://dx.doi.org/10.1158/1078-0432.CCR-04-0272

Kawano, N., H. Osawa, T. Ito, Y. Nagashima, F. Hirahara, Y. Inayama, Y. Nakatani, S. Kimura, H. Kitajima, N. Koshikawa, et al. 1997. Expression of gelatinase A, tissue inhibitor of metalloproteinases-2, matrilysin, and trypsin(ogen) in lung neoplasms: an immunohistochemical study. *Hum. Pathol.* 28:613–622. http://dx.doi.org/10.1016/S0046-8177(97)90085-X

Kerr, K.M., S.J. MacKenzie, S. Ramasami, G.I. Murray, N. Fyfe, A.D. Chapman, M.C. Nicolson, and G. King. 2004. Expression of Fhit, cell adhesion molecules and matrix metalloproteinases in atypical adenomatous hyperplasia and pulmonary adenocarcinoma. *J. Pathol.* 203:638–644. http://dx.doi.org/10.1002/path.1557

Kim, T.H., J.Y. Jung, H.J. Roh, K.Y. Chung, and M.R. Roh. 2014. Comparative Expression of Matrix Metalloproteinases in Internal Malignancies and Paired Cutaneous Metastatic Lesions. *Am. J. Dermatopathol.* In press. http://dx.doi.org/10.1097/DAD.0000000000000184

Kitamura, H., Y. Oosawa, N. Kawano, Y. Kameda, H. Hayashi, Y. Nakatani, N. Udaka, T. Ito, and K. Miyazaki. 1999. Basement membrane patterns, gelatinase A and tissue inhibitor of metalloproteinase-2 expressions, and stromal fibrosis during the development of peripheral lung adenocarcinoma. *Hum. Pathol.* 30:331–338. http://dx.doi.org/10.1016/S0046-8177(99)90013-8

Kodate, M., T. Kasai, H. Hashimoto, K. Yasumoto, Y. Iwata, and H. Manabe. 1997. Expression of matrix metalloproteinase (gelatinase) in T1 adenocarcinoma of the lung. *Pathol. Int.* 47:461–469. http://dx.doi.org/10.1111/j.1440-1827.1997.tb04525.x

Kumaki, F., K. Matsui, T. Kawai, Y. Ozeki, Z.X. Yu, V.J. Ferrans, and W.D. Travis. 2001. Expression of matrix metalloproteinases in invasive pulmonary adenocarcinoma with bronchioloalveolar component and atypical adenomatous hyperplasia. *Am. J. Pathol.* 159:2125–2135. http://dx.doi.org/10.1016/S0002-9440(10)63064-7

Leinonen, T., R. Pirinen, J. Böhm, R. Johansson, and V.M. Kosma. 2008. Increased expression of matrix metalloproteinase-2 (MMP-2) predicts tumour recurrence and unfavourable outcome in non-small cell lung cancer. *Histol. Histopathol.* 23:693–700.

Li, G.H., Y.S. Cui, Q.Y. Wu, X.J. Zhang, and Y.F. Gao. 2013. Clinicopathologic significance of β-catenin and matrix metalloproteinase-2 expression in non-small cell lung cancer. *Med. Oncol.* 30:437. http://dx.doi.org/10.1007/s12032-012-0437-z

Li, M., T. Xiao, Y. Zhang, L. Feng, D. Lin, Y. Liu, Y. Mao, S. Guo, N. Han, X. Di, et al. 2010. Prognostic significance of matrix metalloproteinase-1 levels in peripheral plasma and tumour tissues of lung cancer patients. *Lung Cancer*. 69:341–347. http://dx.doi.org/10.1016/j.lungcan.2009.12.007

Lim, B.J., S.S. Jung, S.Y. Choi, and C.S. Lee. 2010. Expression of metastasis-associated molecules in non-small cell lung cancer and their prognostic significance. *Mol. Med. Rep*. 3:43–49.

Lin, T.S., S.H. Chiou, L.S. Wang, H.H. Huang, S.F. Chiang, A.Y. Shih, Y.L. Chen, C.Y. Chen, C.P. Hsu, N.Y. Hsu, et al. 2004. Expression spectra of matrix metalloproteinases in metastatic non-small cell lung cancer. *Oncol. Rep.* 12:717–723.

Liu, Y., D. Lin, T. Xiao, Y. Ma, Z. Hu, H. Zheng, S. Zheng, Y. Liu, M. Li, L. Li, et al. 2011. An immunohistochemical analysis-based decision tree model for estimating the risk of lymphatic metastasis in pN0 squamous cell carcinomas of the lung. *Histopathology*. 59:882–891. http://dx.doi.org/10.1111/j.1365-2559.2011.04013.x

Matsuo, Y., S. Hashimoto, T. Koga, Y. Yonemitsu, I. Yoshino, K. Sugimachi, H. Honda, K. Masuda, and K. Sueishi. 2004. Growth pattern correlates with the distribution of basement membrane and prognosis in lung adenocarcinoma. *Pathol. Res. Pract.* 200:517–529. http://dx.doi.org/10.1016/j.prp.2004.05.002

Michael, M., B. Babic, R. Khokha, M. Tsao, J. Ho, M. Pintilie, K. Leco, D. Chamberlain, and F.A. Shepherd. 1999. Expression and prognostic significance of metalloproteinases and their tissue inhibitors in patients with small-cell lung cancer. *J. Clin. Oncol.* 17:1802–1808.

Mino, N., K. Takenaka, M. Sonobe, R. Miyahara, K. Yanagihara, Y. Otake, H. Wada, and F. Tanaka. 2007. Expression of tissue inhibitor of metalloproteinase-3 (TIMP-3) and its prognostic significance in resected non-small cell lung cancer. *J. Surg. Oncol.* 95:250–257. http://dx.doi.org/10.1002/jso.20663

Morita, S., A. Sato, H. Hayakawa, H. Ihara, T. Urano, Y. Takada, and A. Takada. 1998. Cancer cells overexpress mRNA of urokinase-type plasminogen activator, its receptor and inhibitors in human non-small-cell lung cancer tissue: analysis by Northern blotting and in situ hybridization. *Int. J. Cancer*. 78:286–292. http://dx.doi.org/10.1002/(SICI)1097-0215(19981029)78:3<286::AID-IJC4>3.0.CO;2-R

Nakagawa, H., and S. Yagihashi. 1994. Expression of type IV collagen and its degrading enzymes in squamous cell carcinoma of lung. *Jpn. J. Cancer Res.* 85:934–938. http://dx.doi.org/10.1111/j.1349-7006.1994.tb02971.x

Nakstad, B., and T. Lyberg. 1991. Immunohistochemical localization of coagulation, fibrinolytic and antifibrinolytic markers in adenocarcinoma of the lung. *APMIS*. 99:981–988. http://dx.doi.org/10.1111/j.1699-0463.1991.tb01288.x

Nawrocki, B., M. Polette, V. Marchand, M. Monteau, P. Gillery, J.M. Tournier, and P. Birembaut. 1997. Expression of matrix metalloproteinases and their inhibitors in human bronchopulmonary carcinomas: quantificative and morphological analyses. *Int. J. Cancer*. 72:556–564. http://dx.doi.org/10.1002/(SICI)1097-0215(19970807)72:4<556::AID-IJC2>3.0.CO;2-P

Oka, T., T. Ishida, T. Nishino, and K. Sugimachi. 1991. Immunohistochemical evidence of urokinase-type plasminogen activator in primary and metastatic tumors of pulmonary adenocarcinoma. *Cancer Res.* 51:3522–3525.

Okudera, K., Y. Kamata, S. Takanashi, Y. Hasegawa, T. Tsushima, Y. Ogura, K. Nakanishi, H. Sato, and K. Okumura. 2006. Small adenocarcinoma of the lung: prognostic significance of central fibrosis chiefly because of its association with angiogenesis and lymphangiogenesis. *Pathol. Int.* 56:494–502. http://dx.doi.org/10.1111/j.1440-1827.2006.01997.x

Ornstein, D.L., L.R. Zacharski, V.A. Memoli, W. Kisiel, B.J. Kudryk, J. Hunt, S.M. Rousseau, and D.C. Stump. 1991. Coexisting macrophage-associated fibrin formation and tumor cell urokinase in squamous cell and adenocarcinoma of the lung tissues. *Cancer*. 68:1061–1067. http://dx.doi.org/10.1002/1097-0142(19910901)68:5<1061::AID-CNCR2820680525>3.0.CO;2-D

Passlick, B., W. Sienel, R. Seen-Hibler, W. Wöckel, O. Thetter, W. Mutschler, and K. Pantel. 2000. Overexpression of matrix metalloproteinase 2 predicts unfavorable outcome in early-stage non-small cell lung cancer. *Clin. Cancer Res.* 6:3944–3948.

Passmore, M.R., M. Nataatmadja, and J.F. Fraser. 2012. Assessment of control tissue for gene and protein expression studies: a comparison of three alternative lung sources. *ScientificWorldJournal*. 2012:523840. http://dx.doi.org/10.1100/2012/523840

Polette, M., B. Nawrocki, C. Gilles, H. Sato, M. Seiki, J.M. Tournier, and P. Birembaut. 1996. MT-MMP expression and localisation in human lung and breast cancers. *Virchows Arch.* 428:29–35. http://dx.doi.org/10.1007/BF00192924

Pritchard, S.C., M.C. Nicolson, C. Lloret, J.A. McKay, V.G. Ross, K.M. Kerr, G.I. Murray, and H.L. McLeod. 2001. Expression of matrix metalloproteinases 1, 2, 9 and their tissue inhibitors in stage II non-small cell lung cancer: implications for MMP inhibition therapy. *Oncol. Rep.* 8:421–424.

Robert, C., I. Bolon, S. Gazzeri, S. Veyrenc, C. Brambilla, and E. Brambilla. 1999. Expression of plasminogen activator inhibitors 1 and 2 in lung cancer and their role in tumor progression. *Clin. Cancer Res.* 5:2094–2102.

Shao, W., W. Wang, X.G. Xiong, C. Cao, T.D. Yan, G. Chen, H. Chen, W. Yin, J. Liu, Y. Gu, et al. 2011. Prognostic impact of MMP-2 and MMP-9 expression in pathologic stage IA non-small cell lung cancer. *J. Surg. Oncol.* 104:841–846. http://dx.doi.org/10.1002/jso.22001

Shou, Y., T. Hirano, Y. Gong, Y. Kato, K. Yoshida, T. Ohira, N. Ikeda, C. Konaka, Y. Ebihara, F. Zhao, and H. Kato. 2001. Influence of angiogenetic factors and matrix metalloproteinases upon tumour progression in non-small-cell lung cancer. *Br. J. Cancer*. 85:1706–1712. http://dx.doi.org/10.1054/bjoc.2001.2137

Song, S.H., J.K. Lee, J.Y. Hur, I. Kim, H.S. Saw, and Y.K. Park. 2006. The expression of epidermal growth factor receptor, vascular endothelial growth factor, matrix metalloproteinase-2, and cyclooxygenase-2 in relation to human papilloma viral load and persistence of human papillomavirus after conization with negative margins. *Int. J. Gynecol. Cancer*. 16:2009–2017. http://dx.doi.org/10.1111/j.1525-1438.2006.00727.x

Stenvold, H., T. Donnem, S. Andersen, S. Al-Saad, K. Al-Shibli, L.T. Busund, and R.M. Bremnes. 2012. Overexpression of matrix metalloproteinase-7 and -9 in NSCLC tumor and stromal cells: correlation with a favorable clinical outcome. *Lung Cancer*. 75:235–241. http://dx.doi.org/10.1016/j.lungcan.2011.06.010

Tang, C., D. Luo, H. Yang, Q. Wang, R. Zhang, G. Liu, and X. Zhou. 2013. Expression of SHP2 and related markers in non-small cell lung cancer: a tissue microarray study of 80 cases. *Appl. Immunohistochem. Mol. Morphol.* 21:386–394. http://dx.doi.org/10.1097/PAI.0b013e31827da3f9

Thomas, P., R. Khokha, F.A. Shepherd, R. Feld, and M.S. Tsao. 2000. Differential expression of matrix metalloproteinases and their inhibitors in non-small cell lung cancer. *J. Pathol.* 190:150–156. http://dx.doi.org/10.1002/(SICI)1096-9896(200002)190:2<150::AID-PATH510>3.0.CO;2-W

Tolnay, E., T. Wiethege, C. Kuhnen, M. Wulf, B. Voss, and K.M. Müller. 1997. Expression of type IV collagenase correlates with the expression of vascular endothelial growth factor in primary non-small cell lung cancer. *J. Cancer Res. Clin. Oncol.* 123:652–658. http://dx.doi.org/10.1007/s004320050120

Urbanski, S.J., D.R. Edwards, A. Maitland, K.J. Leco, A. Watson, and A.E. Kossakowska. 1992. Expression of metalloproteinases and their inhibitors in primary pulmonary carcinomas. *Br. J. Cancer*. 66:1188–1194. http://dx.doi.org/10.1038/bjc.1992.434

Volm, M., J. Mattern, and R. Koomagi. 1999. Relationship of urokinase and urokinase receptor in non-small cell lung cancer to proliferation, angiogenesis, metastasis and patient survival. *Oncol. Rep.* 6:611–615.

Yamamura, T., K. Nakanishi, S. Hiroi, F. Kumaki, H. Sato, S. Aida, and T. Kawai. 2002. Expression of membrane-type-1-matrix metalloproteinase and metalloproteinase-2 in nonsmall cell lung carcinomas. *Lung Cancer*. 35:249–255. http://dx.doi.org/10.1016/S0169-5002(01)00431-7

Yao, L., B. Sun, X. Zhao, X. Zhao, Q. Gu, X. Dong, Y. Zheng, J. Sun, R. Cheng, H. Qi, and J. An. 2014. Overexpression of Wnt5a promotes angiogenesis in NSCLC. *Biomed. Res. Int*. 2014:832562. http://dx.doi.org/10.1155/2014/832562

Yoshino, H., Y. Endo, Y. Watanabe, and T. Sasaki. 1998. Significance of plasminogen activator inhibitor 2 as a prognostic marker in primary lung cancer: association of decreased plasminogen activator inhibitor 2 with lymph node metastasis. *Br. J. Cancer*. 78:833–839. http://dx.doi.org/10.1038/bjc.1998.588

Zhang, Z., A. Wang, B. Sun, Z. Zhan, K. Chen, and C. Wang. 2013. Expression of CLDN1 and CLDN10 in lung adenocarcinoma in situ and invasive lepidic predominant adenocarcinoma. *J. Cardiothorac. Surg.* 8:95. http://dx.doi.org/10.1186/1749-8090-8-95

Zhou, H., A. Wu, W. Fu, Z. Lv, and Z. Zhang. 2014. Significance of semaphorin-3A and MMP-14 protein expression in non-small cell lung cancer. *Oncol. Lett*. 7:1395–1400.

Studies of protease localization in human prostate cancer

Behnsawy, H.M., H. Miyake, K. Harada, and M. Fujisawa. 2013. Expression patterns of epithelial-mesenchymal transition markers in localized prostate cancer: significance in clinicopathological outcomes following radical prostatectomy. *BJU Int.* 111:30–37. http://dx.doi.org/10.1111/j.1464-410X.2012.11551.x

Boag, A.H., and I.D. Young. 1994. Increased expression of the 72-kd type IV collagenase in prostatic adenocarcinoma. Demonstration by immunohistochemistry and in situ hybridization. *Am. J. Pathol.* 144:585–591.

Bodey, B., B. Bodey Jr., S.E. Siegel, and H.E. Kaiser. 2001. Immunocytochemical detection of matrix metalloproteinase expression in prostate cancer. *In Vivo*. 15:65–70.

Boxler, S., V. Djonov, T.M. Kessler, R. Hlushchuk, L.M. Bachmann, U. Held, R. Markwalder, and G.N. Thalmann. 2010. Matrix metalloproteinases and angiogenic factors: predictors of survival after radical prostatectomy for clinically organ-confined prostate cancer? *Am. J. Pathol.* 177:2216–2224. http://dx.doi.org/10.2353/ajpath.2010.091190

Brehmer, B., S. Biesterfeld, and G. Jakse. 2003. Expression of matrix metalloproteinases (MMP-2 and -9) and their inhibitors (TIMP-1 and -2) in prostate cancer tissue. *Prostate Cancer Prostatic Dis.* 6:217–222. http://dx.doi.org/10.1038/sj.pcan.4500657

Cardillo, M.R., F. Di Silverio, and V. Gentile. 2006. Quantitative immunohistochemical and in situ hybridization analysis of metalloproteinases in prostate cancer. *Anticancer Res.* 26(2A):973–982.

Cozzi, P.J., J. Wang, W. Delprado, M.C. Madigan, S. Fairy, P.J. Russell, and Y. Li. 2006. Evaluation of urokinase plasminogen activator and its receptor in different grades of human prostate cancer. *Hum. Pathol.* 37:1442–1451. http://dx.doi.org/10.1016/j.humpath.2006.05.002

Escaff, S., J.M. Fernández, L.O. González, A. Suárez, S. González-Reyes, J.M. González, and F.J. Vizoso. 2011a. Collagenase-3 expression by tumor cells and gelatinase B expression by stromal fibroblast-like cells are associated with biochemical recurrence after radical prostatectomy in patients with prostate cancer. *World J. Urol.* 29:657–663. http://dx.doi.org/10.1007/s00345-010-0595-6

Escaff, S., J.M. Fernández, L.O. González, A. Suárez, S. González-Reyes, J.M. González, and F.J. Vizoso. 2011b. Comparative study of stromal metalloproteases expression in patients with benign hyperplasia and prostate cancer. *J. Cancer Res. Clin. Oncol.* 137:551–555. http://dx.doi.org/10.1007/s00432-010-0906-8

Fernandez-Gomez, J., S. Escaf, L.O. Gonzalez, A. Suarez, S. Gonzalez-Reyes, J. González, O. Miranda, and F. Vizoso. 2011. Relationship between metalloprotease expression in tumour and stromal cells and aggressive behaviour in prostate carcinoma: Simultaneous high-throughput study of multiple metalloproteases and their inhibitors using tissue array analysis of radical prostatectomy samples. *Scand. J. Urol. Nephrol.* 45:171–176. http://dx.doi.org/10.3109/00365599.2010.545074

Gavrilov, D., O. Kenzior, M. Evans, R. Calaluce, and W.R. Folk. 2001. Expression of urokinase plasminogen activator and receptor in conjunction with the ets family and AP-1 complex transcription factors in high grade prostate cancers. *Eur. J. Cancer*. 37:1033–1040. http://dx.doi.org/10.1016/S0959-8049(01)00077-6

Gupta, A., Y. Lotan, R. Ashfaq, C.G. Roehrborn, G.V. Raj, C.C. Aragaki, F. Montorsi, and S.F. Shariat. 2009. Predictive value of the differential expression of the urokinase plasminogen activation axis in radical prostatectomy patients. *Eur. Urol.* 55:1124–1134. http://dx.doi.org/10.1016/j.eururo.2008.06.054

Kogianni, G., M.M. Walker, J. Waxman, and J. Sturge. 2009. Endo180 expression with cofunctional partners MT1-MMP and uPAR-uPA is correlated with prostate cancer progression. *Eur. J. Cancer*. 45:685–693. http://dx.doi.org/10.1016/j.ejca.2008.11.023

Kumano, M., H. Miyake, M. Muramaki, J. Furukawa, A. Takenaka, and M. Fujisawa. 2009. Expression of urokinase-type plasminogen activator system in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy. *Urol. Oncol.* 27:180–186. http://dx.doi.org/10.1016/j.urolonc.2008.01.012

Kuniyasu, H., P. Troncoso, D. Johnston, C.D. Bucana, E. Tahara, I.J. Fidler, and C.A. Pettaway. 2000. Relative expression of type IV collagenase, E-cadherin, and vascular endothelial growth factor/vascular permeability factor in prostatectomy specimens distinguishes organ-confined from pathologically advanced prostate cancers. *Clin. Cancer Res.* 6:2295–2308.

Kuniyasu, H., R. Ukai, D. Johnston, P. Troncoso, I.J. Fidler, and C.A. Pettaway. 2003. The relative mRNA expression levels of matrix metalloproteinase to E-cadherin in prostate biopsy specimens distinguishes organ-confined from advanced prostate cancer at radical prostatectomy. *Clin. Cancer Res.* 9:2185–2194.

Madigan, M.C., E.A. Kingsley, P.J. Cozzi, W.J. Delprado, P.J. Russell, and Y. Li. 2008. The role of extracellular matrix metalloproteinase inducer protein in prostate cancer progression. *Cancer Immunol. Immunother.* 57:1367–1379. http://dx.doi.org/10.1007/s00262-008-0473-x

Maruta, S., H. Sakai, S. Kanda, T. Hayashi, H. Kanetake, and Y. Miyata. 2009. E1AF expression is associated with extra-prostatic growth and matrix metalloproteinase-7 expression in prostate cancer. *APMIS*. 117:791–796. http://dx.doi.org/10.1111/j.1600-0463.2009.02534.x

Matuszak, E.A., and N. Kyprianou. 2013. Expression patterns of epithelial-mesenchymal transition markers in localized prostate cancer: significance in clinicopathological outcomes following radical prostatectomy. *BJU Int.* 111:6–7. http://dx.doi.org/10.1111/j.1464-410X.2012.11566.x

Min, H.J., Y. Lee, X.F. Zhao, Y.K. Park, M.K. Lee, J.W. Lee, and S. Kim. 2014. TMPRSS4 upregulates uPA gene expression through JNK signaling activation to induce cancer cell invasion. *Cell. Signal.* 26:398–408. http://dx.doi.org/10.1016/j.cellsig.2013.08.002

Miyake, H., M. Muramaki, T. Kurahashi, A. Takenaka, and M. Fujisawa. 2010. Expression of potential molecular markers in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy. *Urol. Oncol.* 28:145–151. http://dx.doi.org/10.1016/j.urolonc.2008.08.001

Montironi, R., G. Lucarini, C. Castaldini, C.M. Galluzzi, G. Biagini, and G. Fabris. 1996. Immunohistochemical evaluation of type IV collagenase (72-kd metalloproteinase) in prostatic intraepithelial neoplasia. *Anticancer Res.* 16(4A):2057–2062.